
Cell Reports

Cell-Type-Specific Complement Expression in the Healthy and Diseased Retina

Graphical Abstract



Highlights

- Each retinal cell type expresses a specific signature of complement components
- Müller and RPE cells are the main source of retinal complement transcripts
- Components of the alternative and classical activating pathways were detected
- The cell-type-specific complement signature changes with aging and degeneration

Authors

Diana Pauly, Divyansh Agarwal, Nicholas Dana, ..., Dwight Stambolian, Mingyao Li, Antje Grosche

Correspondence

diana.pauly@ukr.de (D.P.), antje.grosche@med.uni-muenchen.de (A.G.)

In Brief

Overshooting complement activity contributes to retinal degeneration. Pauly et al. demonstrate a distinct complement expression profile of retinal cell types that changes with aging and during retinal degeneration. This prompts the intriguing concept of a local retinal complement activation possibly independent of the systemic components typically produced by the liver.





Cell Reports

Diana Pauly,^{1,12,13,*} Divyansh Agarwal,^{2,12} Nicholas Dana,³ Nicole Schäfer,¹ Josef Biber,⁴ Kirsten A. Wunderlich,⁴ Yassin Jabri,¹ Tobias Straub,⁵ Nancy R. Zhang,⁶ Avneesh K. Gautam,⁷ Bernhard H.F. Weber,⁸ Stefanie M. Hauck,⁹ Mijin Kim,³ Christine A. Curcio,¹⁰ Dwight Stambolian,³ Mingyao Li,¹¹ and Antje Grosche^{4,*} ¹Experimental Ophthalmology, University Hospital Regensburg, Regensburg 93053, Germany

"Experimental Opininamology, Onversity nospital negerisburg, negerisburg 55055, dermany

²Genomics and Computational Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

³Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

⁴Department of Physiological Genomics, Biomedical Center, Ludwig Maximilians University Munich, Planegg-Martinsried 82152, Germany ⁵Core Facility Bioinformatics, Biomedical Center, Ludwig Maximilians University Munich, Planegg-Martinsried 82152, Germany

⁶Department of Statistics, The Wharton School, University of Pennsylvania, Philadelphia, PA 19104, USA

⁷Department of Medicine, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA ⁸Institute of Human Genetics, University of Regensburg, Regensburg 93053, Germany

⁹Research Unit Protein Science, Helmholtz Center Munich, Research Center for Environmental Health (GmbH), Munich 80939, Germany

¹⁰Department of Ophthalmology and Visual Sciences, University of Alabama at Birmingham, Birmingham, AL 35294-0019, USA

¹¹Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA

¹²These authors contributed equally

¹³Lead Contact

*Correspondence: diana.pauly@ukr.de (D.P.), antje.grosche@med.uni-muenchen.de (A.G.)

https://doi.org/10.1016/j.celrep.2019.10.084

SUMMARY

Complement dysregulation is a feature of many retinal diseases, yet mechanistic understanding at the cellular level is limited. Given this knowledge gap about which retinal cells express complement, we performed single-cell RNA sequencing on \sim 92,000 mouse retinal cells and validated our results in five major purified retinal cell types. We found evidence for a distributed cell-type-specific complement expression across 11 cell types. Notably, Müller cells are the major contributor of complement activators c1s, c3, c4, and cfb. Retinal pigment epithelium (RPE) mainly expresses cfh and the terminal complement components, whereas cfi and cfp transcripts are most abundant in neurons. Aging enhances c1s, cfb, cfp, and cfi expression, while cfh expression decreases. Transient retinal ischemia increases complement expression in microglia, Müller cells, and RPE. In summary, we report a unique complement expression signature for murine retinal cell types suggesting a well-orchestrated regulation of local complement expression in the retinal microenvironment.

INTRODUCTION

Single-nucleotide polymorphisms in complement genes are associated with a number of retinal diseases, including glaucoma (Scheetz et al., 2013), age-related macular degeneration (AMD) (Weber et al., 2014), and diabetic retinopathy (Yang et al., 2016; Wang et al., 2013). The immune-privileged retina is among others under regular immune surveillance by proteins of the complement system. Although systemic complement is known to perform homeostatic functions that include opsonization for phagocytosis, formation of membrane attack complexes (MACs), and recruitment of immune cells (Merle et al., 2015), the local regulation of complement within the cellular architecture of the neurosensory retina is poorly understood. Current evidence suggests that complement components are locally expressed in the retinal pigment epithelium (RPE) (Schäfer et al., 2017; Luo et al., 2011; Anderson et al., 2010; Tian et al., 2015; Li et al., 2014; Rutar et al., 2012) as well as microglia (Rutar et al., 2012) and could be independent of the systemic complement, which is produced in hepatocytes and distributed via the bloodstream. A retinal complement system may help facilitate a rapid response to microbial invasion and disposal of damaged cells despite an intact blood-retina barrier.

OPEN

CellPress

Upregulation of complement expression, subsequent protein deposition, and MAC formation have been demonstrated in the normal aging (Chen et al., 2010; Ma et al., 2013; Chen et al., 2008) and diseased retina (Crabb, 2014; Sudharsan et al., 2017; Radu et al., 2011; Zhang et al., 2002; Kuehn et al., 2008). In fact, complement components present in extracellular deposits (termed "drusen") are the hallmark of AMD (Crabb, 2014). Consequently, it is tempting to speculate that a source of complement components during aging could be the retina/ RPE itself, as animal studies have shown increased retinal expression of c1q, c3, c4, and cfb in older mice (Ma et al., 2013; Chen et al., 2010). Complement upregulation has also been observed in retinitis pigmentosa (Sudharsan et al., 2017), Stargardt disease (Radu et al., 2011), and conditions associated with transient ischemic tissue damage, viz. diabetic retinopathy (Zhang et al., 2002) and glaucoma (Andreeva et al., 2014; Kuehn et al., 2008; Kim et al., 2013). Despite a clear indication for a fundamental role of the complement system in the retina, it remains unknown which retinal cell populations shape complement homeostasis in the healthy, aging, and diseased retina.

The retina consists of more than 40 different cell types, which cooperate to capture, process, and transmit visual signals to the brain (Macosko et al., 2015; Tian et al., 2015; Rheaume et al., 2018; Shekhar et al., 2016). Our understanding of the healthy and diseased retina and its supporting tissues like the RPE and choriocapillaris has grown recently (Tian et al., 2015; Pinelli et al., 2016). Transcriptomic studies have focused on the whole retina or RPE but miss information about cell-type-specific transcription (Pinelli et al., 2016; Tian et al., 2015). Droplet-based single-cell RNA sequencing (scRNA-seq) has identified the molecular differences among retinal ganglion cells (Rheaume et al., 2018), bipolar cells (Shekhar et al., 2016), and Müller cells (Roesch et al., 2008), but these studies provided little insight into complement expression of the major retinal cell types and changes occurring with aging and degeneration.

Here, we profile complement expression at the single-cell level in the major 11 retinal cell types of the mouse and further validate these results in enriched Müller cells, vascular cells, microglia, neurons, and RPE cells. We observed a characteristic contribution of complement transcripts from distinct retinal cell populations. Our data suggest that the classical and alternative complement pathway could be activated solely by local complement production and thereby could induce C3 cleavage. CFH is the major complement inhibitor in the mouse retina; retinal stress consistently downregulates *cfh* expression. Moreover, cell-type-specific changes in complement expression differed in aging and acute retinal degeneration induced by transient ischemia, implying a stress-dependent and cell-type-specific modulation of retinal complement homeostasis mediated by the tissue itself.

RESULTS

Single-Cell RNA Sequencing Reveals Complement Component Expression across Multiple Cell Types

Retinal cells, ~92,000 total, were isolated from six male healthy C57BL/6J mice and separated for scRNA-seq (Macosko et al., 2015; Shekhar et al., 2016; Cheng et al., 2013b; Kim et al., 2008). Following sequencing, the data were analyzed using 30 principal components as input to the t-Distributed Stochastic Neighbor Embedding (t-SNE) method for dimension reduction and data visualization (Figures 1A and S1). Cells were classified into eleven major types based on established markers (Tables S1 and S2). We then mapped the expression of complement genes across all 11 cell types and observed a distributed expression of complement components across various resident cells in the retina (Figure 1B; Table S3). We detected cell-type-specific complement expression mainly in the classical pathway via scRNAseq. Moreover, we mapped the cell-type-dependent expression of both soluble and membrane-bound complement regulators (Figure 1C; Table S3) and found main soluble regulators cfh, vtn, and clu. Cell types expressing complement regulators at the highest levels were Müller cells, pericytes, and endothelial cells. Complement receptors, which detect complement activation (anaphylatoxins or opsonins), were only expressed in microglia cells (Figure 1B; Table S3).

The results from scRNA-seq regarding complement component transcription were exemplary validated using RNA fluorescence in situ hybridization (FISH) (Figure 2). Complement component c4 expression colocalized with gfap-positive astrocytes/Müller cells in the retinal ganglion cell layer (GCL) (Figure 2A), which correlated with scRNA-seq data (Figure 1B). The scRNA-seq data were also confirmed for complement regulator cfi, which was specifically detected in bipolar cells both by transcription analyses (Figure 1C) and via RNA-FISH (Figure 2B). Complement receptor c1qbp was detected in all cell populations in RNA sequencing (RNA-seq) (Figure 1B). In line with that, we found a colocalization of c1qpb transcripts with markers of microglia/macrophages (hereafter termed microglia) (tmem119) in the GCL (Figure 2C), but rather evenly distributed signals were detected in all retinal layers except for the inner nuclear layer (INL).

qPCR-Based mRNA Analyses of Purified Neurons, Müller Cells, Microglia, Vascular Cells, and RPE Decipher the Differentially Transcriptional Relevance of Retinal Cells

Though our single-cell analysis uncovered complement expression in different cell types, some complement components remained undetectable or were found in relatively rare cell types at the single-cell level (Table S3). Therefore, we further validated our results on Müller cells, microglia, vascular cells, and retinal neurons purified by immunomagnetic cell separation using quantitative real-time PCR. RPE was purified through manual scratching of eyecups from male and female albino BALB/c and pigmented C57BL/6 mice (Figure 3A) (Grosche et al., 2016). All five cell populations were characterized by the expression of specific marker genes (Figures 3A–3F).

Commonly used housekeeping genes showed high transcriptional and translational variability across different cell types (Figures S2A–S2D) except pyruvate dehydrogenase E1 component subunit beta (pdhb) (Figures S2E and S2F) and isocitrate dehydrogenase 3 (NAD+) beta (idh3b) (Figures S2G and S2H), which had relatively homogeneous expression levels. We decided to use idh3b to determine how distinct cell populations proportionally contributed to the total retinal complement transcriptome, because it showed expression levels similar to those of the complement genes, while gapdh, for example, was expressed at much higher levels and thus appeared to be less appropriate (Figure S2C). Based on idh3b, we estimate that the neuronal fraction contributes 60% of the total retina transcriptome and Müller cells contribute 25% (Figure 4A). Vascular cells and microglia expressed lower levels of idh3b, indicating low cell numbers and/or low transcription activity of these cell types in the mouse retina. Quantifying total RNA by RNA picochip analysis, we found similar RNA quantities in Müller cells (33%), neurons (26%), and the RPE/choroid fraction (22%) per mouse (Figure 4B). In accordance with these results, PDHB protein levels were relatively similar across Müller cells, neurons, and RPE cells (Figure 4C), whereas microglia and vascular cells showed weaker PDHB signals. In agreement with previous reports of cell counts in the mouse, we found neurons make




Figure 1. Single-Cell RNA-Seq of Murine Retina Reveals Complement Expression in Different Cell Types

Distribution of complement expression in normal mouse retina is delineated by single-cell transcriptomics.


(A) Using unsupervised clustering, we detect all 11 major cell classes in the mouse retina; the distinct cell types that passed quality control (described in STAR Methods) are shown in a t-SNE map (out of the 92,343 cells total, 91,798 cells passed the filter of having mitochondrial gene expression <50%, and 200 < unique gene counts <3,500). Percentages of assigned cell types are summarized in the right panel. BC, bipolar cell.

(B) Cell-type-specific expression of complement genes is shown in a heatmap. Mean expression values of the genes were calculated in each cluster by randomly subsampling a population of 100 cells for each cell type. Each row represents a retinal cell type, and each column corresponds to a gene.


(C) The expression of complement regulators among the various retinal cell types is shown by means of a dot plot. Cell types are arranged roughly by their location in the retina, from the inner layer (top) to the outer layer (bottom). The size of each circle (pct.exp) depicts the percentage of cells in which the gene was detected for a given cell type, and its color depicts the average transcript count in the expressing cells (avg.exp.scale). See also Figure S1 and Tables S1–S3.

up 85%, RPE cells 13%, Müller cells 2%, and microglia and vascular cells are less than 1% of all retinal cell types (Figure 4D; Table S2) (Jeon et al., 1998). While Müller cells are a compara-

tively infrequent cell type (2%), they contribute up to one third of the total mRNA content in the retina (Figures 1A, 4A, 4B, and 4D; Table S2). Accordingly, our study provides important



(legend on next page)



insight into the proportional transcriptional activities of these five major cell populations in the retina.

Retinal Cell Populations Express Unique Complement Signatures

Encouraged by the distributed complement expression pattern across 11 cell types (Figures 1B and 1C; Table S3), we hypothesized that specific retinal cell types shape the intraretinal com-

Figure 3. Validation of Enrichment of Different Retinal Cell Types

(A) Schematic view of distinct retinal cell types. Müller cells (blue), the central glia cells of the retina, are in direct contact with the vitreous and various retinal cell types: microglia (green), vascular cells (red), and neurons (gray). 80% of the retinal neurons are light-responsive photoreceptors that are supported by retinal pigment epithelial cells (RPE, brown).

(B) scRNA-seq data illustrating expression of glutamine synthetase (*glul*) across retinal cells (top panels). Murine retinal cell populations were enriched by immunomagnetic cell separation and characterized by quantitative real-time PCR using specific markers (bottom panels); *Glul* is a marker for the Müller cell fraction.

(C) Microglia (and putatively co-enriched macrophages) specifically express *cd11b* (*itgam*).

(D) Vascular cell enrichment was proven by strong expression of *pecam*.

(E) Retinal neurons were characterized by an enhanced detection of the photoreceptor-specific *nrl* mRNA compared to the other cell populations. (F) *Rpe65* was exclusively expressed in RPE/ choroid. Exemplarily shown mean values \pm SEM for cell preparations from BALB/c mice at 8, 16, and 24 weeks of age (n = 4–6 for each age). See also Figure S2 and Table S7.

plement homeostasis through expression of specific complement components. We selected six disease-associated genes (Schäfer et al., 2017; Weber et al., 2014)

(*c1s*, *c3*, *cfb*, *cfp*, *cfh*, and *cfi*) and six supporting complement genes (*c4*, *cfd*, *c5*, *c6*, *c7*, *c8*, and *c9*) for further validation via quantitative real-time PCR and western blot (Figures 4E and 4F) and found that Müller cells contributed the most complement activator transcripts, expressing 47% of *c1s*, 67% of *c4*, and 54% of *c3* retinal transcripts in 8-week-old mice (Figure 4E). Retinal neurons dominated the expression of the complement regulators *cfi* and *cfp*, while 59% of the *cfh*, 45% of the *cfb*,

Figure 2. Localization of Selected Complement Component Transcripts in the Healthy Retina of Pigmented 10-Week-Old Mice via Fluorescence *In Situ* Hybridization

(A) Spots indicative of *c4* transcripts were detected in the GCL and clearly overlap with the very few particles positive for the astrocyte marker *gfap* (arrowheads). No transcripts of *c4* or, as expected, the astrocyte marker *gfap* were detected in the INL or outer nuclear layer (ONL).

(B) *Cfi* expression was very weak in the GCL, with no clear association with cell somata, but was detected at a rather high level in the INL. There, signals partially overlapped with those of the bipolar marker *gsg1* (asterisks). In the ONL, probes detecting *cfi* transcripts produced signals clearly above the autofluorescence background level. A clear distinction regarding whether *cfi* transcripts are localized in photoreceptors and/or in Müller glia that ensheathe photoreceptor somata in the ONL cannot be made.

(C) *clqbp* transcript was rather evenly distributed across the whole retina. A partial overlap with the microglia marker *tmem119* in the GCL could be validated (arrowheads). Note that *c1qbp* transcripts were detected in the inner plexiform layer (IPL), but not in the INL.

(D) *cfh* transcripts were detected at low levels in the GCL and INL, and no clear overlap of signals with that of the ganglion cell marker *pou4f1* was observed. It seemed to be more enriched in the outer plexiform layer (OPL). Similarly, *cfh* transcript levels are low in the ONL. The staining pattern could reflect an expression in Müller glia enwrapping photoreceptor somata.

(E and F) As positive control, probes conjugated either with (E) Quasar 670 (green) or (F) Quasar 570 (red) targeting transcripts of *gapdh* were used. Note the robust detection of the transcript especially in association with cell bodies, which confirms the high expression levels of *gapdh* detected via scRNA-seq. Auto-fluorescence background was detected in the recording channels if no appropriate probe was incubated with the tissue in the GCL, while some autofluorescence background was detected in the OPL and ONL if no appropriate probe was incubated with the tissue. Scale bars, 5 µm.




Figure 4. Contribution of Retinal Cell Types to the Retinal Architecture, Expressome, and Complement Homeostasis

(A) mRNA expression of the housekeeping gene *idh3b* as determined in samples from retinal cell populations enriched from retinae of 8-, 16, and 24-week-old albino mice without adjusting the RNA input amount per cell type. This enables an estimate of the contribution of each cell type to the retinal transcriptome. Bars represent mean values \pm SEM (n = 4–6).

(B) The total RNA amount isolated from retinal cell populations enriched from albino mice (8 to 16 weeks old) was investigated using picochip analysis. Bars represent mean values \pm SEM (n = 5–8).

(C) Quantification of PDHB protein expression via western blots performed on five retinal cell types purified from 4–6 albino mice.

(D) Previously published (Jeon et al., 1998) and our own retinal cell counts in the healthy mouse retina.

(E) Expression levels of indicated complement components were determined from cells of albino mice at mRNA (bars, 8-week-old mice) and at protein level (western blot, 8- to 24-week -old mice). The overall contribution of each cell population to the local complement homeostasis was determined by analyzing the total yield of mRNA or protein derived from the respective cell population so that both are reflected by the data (expression level per cell type and the number of cells per cell type present in the retina).

(F) Scheme of the complement system that can be activated via three different mechanisms and is enhanced by an amplification loop. Note that complement components only detected at the transcript level are delineated in pink, and those that were also confirmed at the protein level are shown in dark pink. Complement components with higher expression in retinal cell types compared to the RPE/choroid fraction are pinpointed by a thick outline. CP, classical pathway; AP, alternative pathway.

See also Figures S2 and S3 and Table S7.




Figure 5. Retinal Phenotype and Complement Homeostasis in Aging Albino Mice

(A) Expression levels of *c1s*, *c3*, *cfb*, *cfp*, *cfh*, and *cfi* were determined from cells of albino mice at the mRNA level (bars) at the indicated ages. The overall putative contribution of each cell population to the local complement homeostasis was determined by analyzing the total yield of mRNA derived from the respective cell population.

(B–D) The quantities of DAPI⁺ cell nuclei in the (B) GCL, (C) INL, and (D) ONL were comparable in 16- to 32-week-old albino retinae.

(E) Left: microglia were quantified in the inner retinal layers (INR) such as ganglion cell and inner plexiform layer and additionally in the outer plexiform layer (OPL) on basis of Iba1 labeling in mice of the indicated age. Right: the area occupied by processes of a single microglia was measured as exemplarily depicted by the dashed circles of different color for OPL microglia in (D). Bars represent mean values \pm SEM from 2–4 animals. *p < 0.05, **p < 0.01, Mann-Whitney *U* test. See also Figure S2 and Table S7.

and 82% of the *cfd* mRNA and *c5–c9* transcripts responsible for the terminal MAC were detected in RPE. Despite the relatively low number of microglia, the resident immune cells of the retina contributed proportionally more *cfh* mRNA and a similar amount of *cfb* transcripts to the retinal complement population compared with retinal neurons.

We confirmed expression of complement activator C1s, CFB, and CFP proteins in all enriched murine cell populations (Figure 4E). Complement C3 protein was detected in RPE, Müller cells, and neurons, while the complement inhibitor CFH and CFI proteins were present in all cell types except the vascular cell population. Alternative pathway protease CFD was identified in the Müller cell and RPE fraction, while C6 was only found in neurons and C7 was detected in Müller cells and neurons. We could not detect C4, C5, and C9 proteins in any of the retinal cell populations (Figure 4E). For C8, no specific antibody was commercially available. There was an overlap in the complement transcript levels determined by quantitative real-time PCR and that of the complement proteins detected in various cell populations. For example, the strong c1s mRNA expression found in Müller cells matched the robust C1s protein levels, and cfd mRNA expression corresponded with CFD protein detection in RPE. Interestingly, neurons expressed ~40% of the total cfp mRNA, whereas CFP protein levels were highest in microglia (Figure 4E). This may imply a spatial separation of complement component transcription and complement component accumulation at the protein level within the retina.

Age-Dependent Changes in the Complement Expression of Different Retinal Cell Populations

We further investigated age-dependent changes in expression levels of known disease associated complement transcripts via quantitative real-time PCR among the different retinal cell populations in mice from 8 to 24 weeks of age. C1s. cfb. cfp. and cfi transcripts increased with age among all cell populations (Figure 5A). Upregulated c1s expression in RPE cells lead to doubling of the total retinal c1s mRNA between 8 and 24 weeks (Figure 5A). Transcripts of the alternative pathway activator cfb, primarily produced by Müller cells and RPE, increased at 16 and 24 weeks of age. The largest increase in cfb transcript levels (2.6fold) was found in the microglial population between 8 and 24 weeks (Figure 5A). The highest proportional contribution of cfp retinal transcripts came from neurons (55%) at 8 weeks of age, and this contribution further increased to 73% at 16/ 24 weeks of age (Figure 5A). In contrast, c3 expression remained relatively stable (Figure 4E), except for the vascular cell population, where the c3 levels dropped by 50% between 8- and 24week-old mice (Figure 5A).

CFH is the main negative regulator of the complement system. We found that *cfh* expression decreased by 50% in all cell populations in 24-week-old mice compared to 8-week-old mice. In 24-week-old mice, RPE cells produced the majority of the retinal *cfh* (Figure 5A), although the majority of the *cfi* transcripts (which act together with CFH) were produced by neurons, specifically rod bipolar cells (Figures 1C and 5A). Together with its functional counterpart, *cfp*, the expression of *cfi* also increased in neurons of 24-week-old mice compared to the 8- and 16-week-old mice (Figure 5A).

These divergent changes in the local complement expression in the retina of aging mice were not accompanied by any detectable retinal cell loss (Figures 5B–5D) but were accompanied by




Figure 6. Comparison of Complement Component Expression between Retinal Cell Types of Aging Mice

(A) Expression of complement components was determined by quantitative real-time PCR. Diagrams represent the relative amount of transcripts per cell (normalized to the *idh3b* housekeeper expression) of the different complement components in the respective cell type enriched from mice at the indicated age. Note the high expression level of inhibitory complement factors in RPE/ choroid samples as well as in microglial and vascular cells, while complement-activating genes appear to dominate in Müller cells and neurons. Data were collected from 4–6 wild-type albino mice (numbers are given in Table S4).

(B) Complement expression analysis by quantitative real-time PCR was performed on enriched retinal cell types from 8-, 16-, and 24-week-old mice. Bars represent mean values \pm SEM of cells purified from 4-6 animals. Mann-Whitney *U* testing was performed on all data. A circle indicates a significant difference compared to the expression level at 8 weeks of age; whereas a diamond indicates a significant difference compared to the expression level at 16 weeks of age. °/ \diamond p < 0.05; ° °/ \diamond ϕ < 0.01.

See also Figure S2 and Table S7.

increased microglia numbers (Figure 5E) and enhanced microglial activation, as suggested by a decreased occupied area of microglial processes (Figure 5E).

A Characteristic Proportion of Activating and Inhibiting Complement Transcripts in Distinct Retinal Cell Types

Having noted a cell-type-specific complement expression in our data, we sought to understand the balance of complement activator and inhibitor expression in the different cell types by normalizing complement expression levels to the housekeeping gene to allow a comparison between cell populations independent of cell counts (Figure 6). Strikingly, we discovered that certain cell types like RPE and microglia mainly express inhibitory complement components (*cfh* and *cfi*), whereas other cell populations, such as neurons and Müller cells, mostly express complement activators (*c1s, c3, cfb,* and *cfp*) (Figure 6A). Interestingly, neurons expressed more *cfi* than *cfh* than the remaining cell types (Figure 6A).

Finally, we checked for age-dependent changes in the expression of the respective complement components—now, in contrast to results presented in Figure 5A, independent of putative changes in cell numbers. We could confirm a significant upregulation of complement activators such as *c1s*, *c3*, *cfb*, and *cfp* with increasing age (Figure 6B). Most of these changes were detected in RPE cells but at later stages (e.g., 24-weekold mice) also in microglia, vascular, and Müller cells. Expression changes of complement inhibitors were not consistent across cell types. While *cfh* was significantly downregulated in Müller glia in mice at 16 weeks of age, it was upregulated in RPE. Moreover, *cfi* was significantly downregulated in microglia but upregulated in Müller glia, retinal neurons, and RPE.

The spatial distribution of complement activators and regulators signifies a unique complement signature for each retinal cell type that was dynamically changing, even though relatively short intervals of aging were investigated.

Acute Ischemic Retinal Injury Triggers Robust Cell-Type-Specific Complement Expression

Retinal tissue injury is a common manifestation of retinal disease. To evaluate how tissue injury might change cell-type-specific complement expression, we used a retinal ischemia/reperfusion (I/R) injury model to induce acute retinal degeneration (Wagner et al., 2017). We found a significant increase in the expression of complement activators 24 h post-ischemia in the different isolated cell populations (Figure 7). Consistent with our previous results, cfi appeared to be the main complement inhibitor in neurons, whereas cfh was the major complement inhibitor expressed in the remaining cell populations. Compared to aging retina (Figures 5 and 6), the upregulation of c1s, c3, cfb, and cfi transcript expression of was more pronounced in postischemic retina at the mRNA level (Figures 7A-7C). Interestingly, this response in c1s, c3, and cfb expression was provoked by changes in the RPE. Moreover, cfh and cfi showed again a mutually opposite pattern of expression changes whereby cfh mRNA decreased and *cfi* increased in I/R retinae (Figure 7C). Detection of C3 (Figure 7D) and C1s (Figure 7E) at protein level via immunolabeling 3 days after the ischemic tissue injury was performed to enable detection of newly formed protein. C1s puncta were evenly distributed over all retinal layers, with a slight enrichment




Figure 7. Transient Ischemic Stress Results in Cell-Type-Specific Upregulation of Transcripts from Activating Complement Components and Downregulation of *cfh*

(A) The relative amount of complement transcripts per retinal cell type indicated that complement-activating transcripts are more abundant in pigmented mice than in albino mice in which transcripts of complement inhibitors dominate at the same age. Note the strong relative upregulation and the resulting shift toward transcripts from complement activators 24 h after transient ischemic retinal stress in all retinal cell types of C57BL/6 mice (numbers are given in Table S5). (B) Major changes of local complement expression (normalized to the housekeeper) were detected by quantitative real-time PCR 24 h after transient ischemia. The most pronounced upregulation of complement activators was found in Müller cells (c3 and cfb), microglia (c3, cfb, and cfp) and RPE (c1s and c3). Cfh was downregulated in Müller cells, while cfi was upregulated in all investigated cell types. Significantly different expression as compared to that cells from healthy

control eyes is indicated (*p < 0.05, **p < 0.01, Mann-Whitney U test). (C) Complement transcript contribution of the different retinal cell populations (no normalization to the housekeeper and no adjustment of RNA input) indicated a pro-inflammatory milieu in the post-ischemic retina. Müller cells, microglia, and RPE cells mainly contributed to the changed complement homeostasis in post-

ischemic retinae.

(legend continued on next page)

in the GCL and RPE (Figure 7D). Similarly, C3 labeling was observed in all retinal layers, and a moderate rise in labeling intensity could be observed 3 days after the ischemic tissue injury, especially in the outer retina affecting photoreceptors and RPE (Figure 7E). Complement components are typically secreted by the producing cells. In line with this fact, we did not find a perfect cell-type-specific match of protein distribution compared to the transcript signatures described above. It has to be considered that ischemic damage may lead to transient breakdown of the blood retinal barrier and that the complement components detected via this approach could also be derived from the systemic complement system, at least in post-ischemic tissue.

DISCUSSION

Since the retina is an immune-privileged tissue, understanding its local complement system is critical to our understanding of retinal inflammation. To identify the retinal cell types expressing complement, we isolated and sequenced ~92,000 cells from healthy mouse retinae. scRNA-seg was validated by RNA-FISH analysis for selected genes and 12 complement components by assays of RNA and protein in enriched cell populations of Müller cells, microglia, vascular cells, retinal neurons, and RPE. Collectively, our results show that complement components are locally expressed by different retinal cell populations, challenging the conventional belief that the complement source in the retina is confined to resident immune cells. We detected complement transcripts and proteins that were produced at higher levels in the neuroretina than in RPE that would be sufficient to activate the classical and/or alternative complement pathway. In consequence, cleavage of C3 into its anaphylatoxin C3a and opsonin C3b could be performed independently of blood-derived complement components (Figure 4F). Complement transcripts of the components that are key to MAC assembly were primarily detected in RPE and rarely found as proteins in the neuroretina. The RPE forms the outer retina-blood barrier. which is able to secrete substrates not only toward the subretinal space (apical) but also toward the choroidal side (basal). Considering its complement expression profile and the largely understudied idea of a context-specific apical or basal secretion pattern of complement by RPE sitting at the blood-retinal interface, it is tempting to speculate that by doing so, the RPE could actively shape the complement homeostasis of the retina, which needs to be addressed in future studies.

Given the cell-specific ratios of activating and inhibiting complement component expression levels, each cell type appears to have a specific role in maintaining retinal complement homeostasis. Moreover, cell populations present in the retina at relatively low numbers, such as microglia and Müller cells (Jeon et al., 1998), seem to have a major impact on retinal complement expression levels. We found that these cells contribute substantially to the total retinal transcriptome. This suggests that quantification of cell numbers alone is insufficient to draw conclusions about the contribution of cellular activity to the global expression profile of the retina. Nonetheless, it has been shown that transcription is tightly regulated according to cell size, and cells with larger cell bodies, such as Müller cells, can provide more mRNA than the more abundant cells with a smaller volume (e.g., neurons and RPE) (Marguerat and Bähler, 2012; Kempe et al., 2015).

The complement system helps maintain normal ocular functions (Sohn et al., 2003, 2000), and its dysregulation significantly influences retinal disease (Sudharsan et al., 2017; Radu et al., 2011; Weber et al., 2014; Yang et al., 2016; Scheetz et al., 2013). Although earlier studies have found low background expression of complement in retinal microglia (Luo et al., 2011; Schäfer et al., 2017; Anderson et al., 2010; Rutar et al., 2012) and RPE/choroid (Schäfer et al., 2017; Luo et al., 2011, 2013), our results unequivocally show that other cell types are capable of local complement production. We did observe expression differences between the scRNA-seq and the MACS-enriched cell populations that can be explained by the lower sensitivity to detect gene expression compared to quantitative real-time PCR. For instance, compared to the single-cell analysis, quantitative real-time PCR allowed us to more readily detect the expression of c1s and c3 in Müller cells, cfp in microglia and vascular cells, cfb in all major retinal cell types, and cfd, c5-c9 mainly in RPE cells. Still, both approaches converged in their assessment of cell-type-specific expression for most complement components. Our results also add to previous work on retinal complement in humans (Tian et al., 2015; Li et al., 2014; Anderson et al., 2010), mice (Schäfer et al., 2017; Luo et al., 2011), and rats (Rutar et al., 2012) by also detecting protein expression for nine complement components that reflect their RNA expression.

The regulation of complement expression in whole-cell populations from the aging retina largely matched the changes we calculated for the normalized cellular expression rates in the distinct cell types. This implies that expression changes were driven by changes at the transcriptional level, not by changes in cell numbers, in accordance with the data from our morphometric analyses performed on aging BALB/c mice. Interestingly, the relative expression of all tested complement components increased in the whole-RPE-cell population with increasing age, except for cfh, whose expression decreased. We speculate that increased single-cell cfh expression alone is unable to counterbalance the overall age-associated RPE dysfunction and/or degeneration (as also indicated by a reduced rpe65 expression). Accordingly, RPE-dependent cfh transcripts decrease at 24 weeks, the putative contribution of *cfh* in regulating the alternative complement pathway in the retinal microenvironment could be diminished, and the intraretinal milieu could be misbalanced.

We also discovered that healthy neurons produce the complement regulators *cfp* and *cfi*. The relevance of these complement

⁽D) Representative immunostaining of complement component C1S and C3 in the healthy and post-ischemic pigmented retina 3 days after injury. Sections were co-labeled for the Müller cell marker glutamine synthetase (GLUL), and nuclei were visualized by DAPI co-labeling.

⁽E) Representative micrographs of retinal sections incubated with the combination of secondary antibodies and DAPI only.

GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer; RPE, retinal pigment epithelium. Scale bars, 20 μm. In (A) and (B), data were collected from 3 – 5 animals. See also Figure S2 and Table S7.

components has already been shown for AMD (Fritsche et al., 2016; Weber et al., 2014; Micklisch et al., 2017). In murine models of retinal degeneration, *cfi* expression increases after polyethylene-glycol-induced insult, whereas *cfp* expression decreases in the light-damaged retina (Schäfer et al., 2017; Lyzo-gubov et al., 2014). Our single cell analysis demonstrated that *cfi* mRNA localizes specifically to rod bipolar cells and protein detection to neurons and Müller cells in mice. CFI inactivates the complement system, and the resulting cleavage products modulate the activity of phagocytes. Rods primarily govern scotopic vision, and mice have a rod-dominated retina similar to humans (except for the *fovea centralis*). This rod-bipolarcell-specific *cfi* transcription in the mouse retina further suggests that the retinal complement system is influenced by functional and anatomical characteristics of the retina.

Age-related anatomical alterations in the retina have been demonstrated in histological analyses (Grossniklaus et al., 2013). Consistent with previous results (Damani et al., 2011; Friedman and Ts'o, 1968), we found increased microglial and decreased RPE marker gene expression with aging. In our study, the expression of complement transcripts c1s, cfb, cfp, and cfi increased while that of cfh decreased in retinal cells between 8 and 24 weeks of age. This indicates a role for complement in retinal adaptation during maturation and with processes of aging (Mukai et al., 2018). Although age-dependent upregulation of complement transcripts, including that of c1q, c3, c4, and cfb, in the retina has been described (Chen et al., 2010), our findings add a role for microglia in the expression of c3 and cfb. Our results also show that Müller cells and neurons provide a substantial proportion of retinal complement transcripts and, thus, their impact on retinal complement homeostasis has likely been underestimated by past studies. Cell culture studies have suggested that Müller glia can produce C1q (Astafurov et al., 2014) and that complement activation products can regulate Müller cell activity via C5a-receptor and influence retinal disease (Cheng et al., 2013a). Our results show a direct involvement of Müller cells in the transcript expression of the retinal complement components, and it is likely that in the retina, similar to the brain, neurons and glia cells orchestrate complement-mediated maturation of nervous tissue via synaptic pruning, progenitor proliferation, and neuronal migration (Tenner et al., 2018). Aging and Alzheimer disease brains increase expression of c1q, c3, and c4 (Walker and McGeer, 1992; Cribbs et al., 2012), which might point to a general mechanism of local complement function in the overall aging of the CNS.

Ischemia and subsequent reperfusion (e.g., upon treatment with anti-VEGF therapy) are associated with diabetic retinopathy (Silva et al., 2015; Traveset et al., 2016; Levin et al., 2017), and polymorphisms in CFB and CFH (Wang et al., 2013) have been implicated in modifying disease progression. We identified Müller cells as a major cell type involved in this process (by downregulating *cfh* transcripts and upregulating *cfb*) in the analysis of post-ischemic mouse retina. Gene profiling studies of whole mouse retinas also suggest an important role of the complement pathway in I/R-associated damage (Andreeva et al., 2014). Retinal *c1q*, *c1s*, *c1r*, *c2*, *c3*, *c4a*, and *cfh* expression has been reported after transient ischemia in mice (Kuehn et al., 2008; Kim et al., 2013; Andreeva et al., 2014). However,

it remains undetermined how individual retinal cell types modulate complement activity after retinal I/R injury. Here, we show that mainly Müller cells, microglia, and RPE increase *c3* and *cfb* expression following ischemia, while *cfp* is upregulated primarily in microglia. The complement inhibitor *cfi* also showed cell-type-specific enhanced mRNA levels in microglia, RPE, and retinal neurons, whereas expression of the complement inhibitor *cfh* was significantly reduced in Müller cells following ischemia. These expression changes suggest augmentation of local complement components following ischemia.

Genetic variation in several complement genes, such as CFH and CFI, are associated with AMD, glaucoma, and central serous retinopathy (Fritsche et al., 2016; Weber et al., 2014; Grassmann et al., 2016). CFI, along with cofactor CFH, regulates complement activity by degrading complement components C3b and C4b (Davis et al., 1984), thereby facilitating the cleavage of C3b into inactive fragments (Sim et al., 1993). We discovered a spatially distinct transcription pattern of cfi and its cofactor, cfh. cfi was mainly detected in retinal neurons (specifically rod bipolar cells), while cfh was detected primarily in vascular and RPE cells. Further, we found opposing transcriptional regulation of cfi and cfh during aging and ischemia. These findings hint at a CFHindependent function of CFI in the retina, perhaps in conjunction with other cofactors such as CR1 or CD46 (Sim et al., 1993). To date, there are no known AMD-associated polymorphisms in the cd46 or cr1 genes, but cd46 knockout induces retinal degeneration (Lyzogubov et al., 2016), highlighting its relevant role in retinal physiology.

Given the cell-type-specific expression profile of complement genes in the retina, we propose that a balanced local complement expression is linked to normal retinal integrity. Moreover, our data show that changes in local, cell-type-specific complement expression during aging and acute stress can be induced by cell stress and retinal degeneration and, thus, could in the end also contribute to disease progression. For example, a reaction common to I/R damage and aging appears to be the decrease of intraretinal expression of the complement inhibitor *cfh*. This working hypothesis of course needs further validation at the functional level by future studies.

Taken together, our cell-type-specific analyses provide an alternative perspective on how expression of complement genes, such as those identified by a genome-wide association study (GWAS) for AMD and diabetic retinopathy, in various retinal cell types might be involved in the disease mechanisms in question. The tightly orchestrated reaction of all retinal cell types to distinct conditions of tissue stress suggests that cell-type-specific responses must be considered for successful development of therapeutic strategies targeting retinal complement activity in the future.

Finally, it needs to be pointed out that the analysis of complement activation and its putative role during retinal development, aging, and retinal degeneration was beyond the scope of the present study that was primarily set up to generate a detailed retinal complement expression atlas. However, complement function in the aforementioned processes (irrespective of its source) has been partially addressed and demonstrated by other research groups in the field (Sohn et al., 2003, 2000; Radu et al., 2011; Scheetz et al., 2013; Sudharsan et al., 2017; Weber et al.,

2014; Yang et al., 2016). We would like to point out that those local complement transcripts we were able to detect in distinct retinal cell types are sufficient to activate the classical and alternative complement pathways. Given the rather low expression of components of the terminal canonical complement pathway in cells from the neuroretina, it remains debatable whether it can be intraretinally active without input from the RPE that did produce moderate levels of respective transcripts and/or the systemic complement system. However, we also would like to stress the point that those complement components we demonstrated to be locally expressed are likely to have non-canonical functions in the retina (e.g., C3 in synapse pruning or CFH in phagocytosis or apoptosis) (Martin et al., 2016; Hawksworth et al., 2017). There is growing evidence for intracellular functions of early complement components, which could have an impact on normal cellular physiology (Liszewski et al., 2017). To follow up this intriguing line of thinking, future studies are needed to identify these intracellular functions in addition to their cell secretion and functional interactions.

STAR***METHODS**

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- LEAD CONTACT AND MATERIALS AVAILABILITY
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
- METHOD DETAILS
 - Retinal ischemia/ reperfusion injury
 - Single Cell RNA Analysis of mouse retina
 - O RNA-FISH
 - MACS enrichment of retinal cell types
 - gRT-PCR
 - O LC-MS/MS mass spectrometry analysis
 - Western blot
 - Immunofluorescent labeling of retina and RPE
- QUANTIFICATION AND STATISTICAL ANALYSIS
- DATA AND CODE AVAILABILITY

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at https://doi.org/10.1016/j. celrep.2019.10.084.

ACKNOWLEDGMENTS

We thank Gabriele Jäger, Dirkje Felder, Renate Foeckler, Andrea Dannullis, and Elfriede Eckert for excellent technical support for cell preparation, immunodetection, and molecular biology. This project was supported by the Deutsche Forschungsgemeinschaft (grant DFG-GR 4403/5-1 to A.G. and grant DFG-PA 1844/3-1 to D.P.) and the Macula Vision Research Foundation (D.S., M.L., and C.A.C.), with institutional support from the EyeSight Foundation of Alabama and Research to Prevent Blindness (C.A.C.); the NIH (grant R01EY030192 to D.S. and M.L.; grants R01GM108600 and R01GM125301 to M.L.; and grant SR01-HG006137 to N.R.Z.); and by a Blavatnik Family Fellowship (D.A.).

AUTHOR CONTRIBUTIONS

D.P., D.A., N.R.Z., A.K.G., S.M.H., M.L., D.S., and A.G.K. designed research; D.P., D.A., N.S., J.B., K.A.W., Y.J., T.S., N.R.Z., S.M.H., M.K., D.S., M.L., and A.G. performed research; D.P., D.A., N.D., N.S., J.B., K.A.W., Y.J., T.S., N.R.Z., B.H.F.W., S.M.H., M.K., D.S., M.L., and A.G. analyzed and interpreted the data; D.P., D.A., C.A.C., D.S., and A.G. wrote the manuscript; and all authors provided input to edit the manuscript.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: January 11, 2019 Revised: May 24, 2019 Accepted: October 22, 2019 Published: November 26, 2019

SUPPORTING CITATIONS

The following references appear in the Supplemental Information: Cheng et al., 2013a

REFERENCES

Anderson, D.H., Radeke, M.J., Gallo, N.B., Chapin, E.A., Johnson, P.T., Curletti, C.R., Hancox, L.S., Hu, J., Ebright, J.N., Malek, G., et al. (2010). The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog. Retin. Eye Res. 29, 95–112.

Andreeva, K., Zhang, M., Fan, W., Li, X., Chen, Y., Rebolledo-Mendez, J.D., and Cooper, N.G. (2014). Time-dependent gene profiling indicates the presence of different phases for ischemia/reperfusion injury in retina. Ophthalmol. Eye Dis. *6*, 43–54.

Astafurov, K., Dong, C.Q., Panagis, L., Kamthan, G., Ren, L., Rozenboym, A., Perera, T.D., Coplan, J.D., and Danias, J. (2014). Complement expression in the retina is not influenced by short-term pressure elevation. Mol. Vis. *20*, 140–152.

Chen, H., Liu, B., Lukas, T.J., and Neufeld, A.H. (2008). The aged retinal pigment epithelium/choroid: a potential substratum for the pathogenesis of age-related macular degeneration. PLoS ONE *3*, e2339.

Chen, M., Muckersie, E., Forrester, J.V., and Xu, H. (2010). Immune activation in retinal aging: a gene expression study. Invest. Ophthalmol. Vis. Sci. *51*, 5888–5896.

Cheng, L., Bu, H., Portillo, J.-A.C., Li, Y., Subauste, C.S., Huang, S.S., Kern, T.S., and Lin, F. (2013a). Modulation of retinal Müller cells by complement receptor C5aR. Invest. Ophthalmol. Vis. Sci. *54*, 8191–8198.

Cheng, C.L., Djajadi, H., and Molday, R.S. (2013b). Cell-specific markers for the identification of retinal cells by immunofluorescence microscopy. Methods Mol. Biol. *935*, 185–199.

Crabb, J.W. (2014). The proteomics of drusen. Cold Spring Harb. Perspect. Med. 4, a017194.

Cribbs, D.H., Berchtold, N.C., Perreau, V., Coleman, P.D., Rogers, J., Tenner, A.J., and Cotman, C.W. (2012). Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study. J. Neuroinflammation 9, 179.

Damani, M.R., Zhao, L., Fontainhas, A.M., Amaral, J., Fariss, R.N., and Wong, W.T. (2011). Age-related alterations in the dynamic behavior of microglia. Aging Cell *10*, 263–276.

Davis, A.E., 3rd, Harrison, R.A., and Lachmann, P.J. (1984). Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g. J. Immunol. *132*, 1960–1966.

Friedman, E., and Ts'o, M.O. (1968). The retinal pigment epithelium. II. Histologic changes associated with age. Arch. Ophthalmol. 79, 315–320.

Frik, J., Merl-Pham, J., Plesnila, N., Mattugini, N., Kjell, J., Kraska, J., Gómez, R.M., Hauck, S.M., Sirko, S., and Götz, M. (2018). Cross-talk between monocyte invasion and astrocyte proliferation regulates scarring in brain injury. EMBO Rep. *19*, e45294.

Fritsche, L.G., IgI, W., Bailey, J.N.C., Grassmann, F., Sengupta, S., Bragg-Gresham, J.L., Burdon, K.P., Hebbring, S.J., Wen, C., Gorski, M., et al. (2016). A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat. Genet. *48*, 134–143.

Grassmann, F., Cantsilieris, S., Schulz-Kuhnt, A.-S., White, S.J., Richardson, A.J., Hewitt, A.W., Vote, B.J., Schmied, D., Guymer, R.H., Weber, B.H.F., and Baird, P.N. (2016). Multiallelic copy number variation in the complement component 4A (C4A) gene is associated with late-stage age-related macular degeneration (AMD). J. Neuroinflammation *13*, 81.

Grosche, A., Hauser, A., Lepper, M.F., Mayo, R., von Toerne, C., Merl-Pham, J., and Hauck, S.M. (2016). The proteome of native adult Müller glial cells from murine retina. Mol. Cell. Proteomics *15*, 462–480.

Grossniklaus, H.E., Nickerson, J.M., Edelhauser, H.F., Bergman, L.A.M.K., and Berglin, L. (2013). Anatomic alterations in aging and age-related diseases of the eye. Invest. Ophthalmol. Vis. Sci. *54*, ORSF23-7.

Hawksworth, O.A., Coulthard, L.G., and Woodruff, T.M. (2017). Complement in the fundamental processes of the cell. Mol. Immunol. *84*, 17–25.

Jeon, C.J., Strettoi, E., and Masland, R.H. (1998). The major cell populations of the mouse retina. J. Neurosci. *18*, 8936–8946.

Kempe, H., Schwabe, A., Crémazy, F., Verschure, P.J., and Bruggeman, F.J. (2015). The volumes and transcript counts of single cells reveal concentration homeostasis and capture biological noise. Mol. Biol. Cell *26*, 797–804.

Kim, D.S., Ross, S.E., Trimarchi, J.M., Aach, J., Greenberg, M.E., and Cepko, C.L. (2008). Identification of molecular markers of bipolar cells in the murine retina. J. Comp. Neurol. *507*, 1795–1810.

Kim, B.-J., Braun, T.A., Wordinger, R.J., and Clark, A.F. (2013). Progressive morphological changes and impaired retinal function associated with temporal regulation of gene expression after retinal ischemia/reperfusion injury in mice. Mol. Neurodegener. *8*, 21.

Kuehn, M.H., Kim, C.Y., Jiang, B., Dumitrescu, A.V., and Kwon, Y.H. (2008). Disruption of the complement cascade delays retinal ganglion cell death following retinal ischemia-reperfusion. Exp. Eye Res. *87*, 89–95.

Lepper, M.F., Ohmayer, U., von Toerne, C., Maison, N., Ziegler, A.-G., and Hauck, S.M. (2018). Proteomic landscape of patient-derived CD4+ T cells in recent-onset type 1 diabetes. J. Proteome Res. *17*, 618–634.

Levin, A.M., Rusu, I., Orlin, A., Gupta, M.P., Coombs, P., D'Amico, D.J., and Kiss, S. (2017). Retinal reperfusion in diabetic retinopathy following treatment with anti-VEGF intravitreal injections. Clin. Ophthalmol. *11*, 193–200.

Li, M., Jia, C., Kazmierkiewicz, K.L., Bowman, A.S., Tian, L., Liu, Y., Gupta, N.A., Gudiseva, H.V., Yee, S.S., Kim, M., et al. (2014). Comprehensive analysis of gene expression in human retina and supporting tissues. Hum. Mol. Genet. 23, 4001–4014.

Liszewski, M.K., Elvington, M., Kulkarni, H.S., and Atkinson, J.P. (2017). Complement's hidden arsenal: New insights and novel functions inside the cell. Mol. Immunol. 84, 2–9.

Luo, C., Chen, M., and Xu, H. (2011). Complement gene expression and regulation in mouse retina and retinal pigment epithelium/choroid. Mol. Vis. *17*, 1588–1597.

Luo, C., Zhao, J., Madden, A., Chen, M., and Xu, H. (2013). Complement expression in retinal pigment epithelial cells is modulated by activated macro-phages. Exp. Eye Res. *112*, 93–101.

Lyzogubov, V.V., Bora, N.S., Tytarenko, R.G., and Bora, P.S. (2014). Polyethylene glycol induced mouse model of retinal degeneration. Exp. Eye Res. *127*, 143–152.

Lyzogubov, V.V., Bora, P.S., Wu, X., Horn, L.E., de Roque, R., Rudolf, X.V., Atkinson, J.P., and Bora, N.S. (2016). The complement regulatory protein CD46 deficient mouse spontaneously develops dry-type age-related macular degeneration-like phenotype. Am. J. Pathol. *186*, 2088–2104. Ma, W., Cojocaru, R., Gotoh, N., Gieser, L., Villasmil, R., Cogliati, T., Swaroop, A., and Wong, W.T. (2013). Gene expression changes in aging retinal microglia: relationship to microglial support functions and regulation of activation. Neurobiol. Aging *34*, 2310–2321.

Macosko, E.Z., Basu, A., Satija, R., Nemesh, J., Shekhar, K., Goldman, M., Tirosh, I., Bialas, A.R., Kamitaki, N., Martersteck, E.M., et al. (2015). Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. Cell *161*, 1202–1214.

Mages, K., Grassmann, F., Jägle, H., Rupprecht, R., Weber, B.H.F., Hauck, S.M., and Grosche, A. (2019). The agonistic TSPO ligand XBD173 attenuates the glial response thereby protecting inner retinal neurons in a murine model of retinal ischemia. J. Neuroinflammation *16*, 43.

Marguerat, S., and Bähler, J. (2012). Coordinating genome expression with cell size. Trends Genet. *28*, 560–565.

Martin, M., Leffler, J., Smoląg, K.I., Mytych, J., Björk, A., Chaves, L.D., Alexander, J.J., Quigg, R.J., and Blom, A.M. (2016). Factor H uptake regulates intracellular C3 activation during apoptosis and decreases the inflammatory potential of nucleosomes. Cell Death Differ. 23, 903–911.

Merle, N.S., Church, S.E., Fremeaux-Bacchi, V., and Roumenina, L.T. (2015). Complement system part I - molecular mechanisms of activation and regulation. Front. Immunol. *6*, 262.

Micklisch, S., Lin, Y., Jacob, S., Karlstetter, M., Dannhausen, K., Dasari, P., von der Heide, M., Dahse, H.-M., Schmölz, L., Grassmann, F., et al. (2017). Age-related macular degeneration associated polymorphism rs10490924 in ARMS2 results in deficiency of a complement activator. J. Neuroinflammation *14*, 4.

Mukai, R., Okunuki, Y., Husain, D., Kim, C.B., Lambris, J.D., and Connor, K.M. (2018). The complement system is critical in maintaining retinal integrity during aging. Front. Aging Neurosci. *10*, 15.

Pannicke, T., Frommherz, I., Biedermann, B., Wagner, L., Sauer, K., Ulbricht, E., Härtig, W., Krügel, U., Ueberham, U., Arendt, T., et al. (2014). Differential effects of P2Y1 deletion on glial activation and survival of photoreceptors and amacrine cells in the ischemic mouse retina. Cell Death Dis. 5, e1353.

Pinelli, M., Carissimo, A., Cutillo, L., Lai, C.-H., Mutarelli, M., Moretti, M.N., Singh, M.V., Karali, M., Carrella, D., Pizzo, M., et al. (2016). An atlas of gene expression and gene co-regulation in the human retina. Nucleic Acids Res. *44*, 5773–5784.

Radu, R.A., Hu, J., Yuan, Q., Welch, D.L., Makshanoff, J., Lloyd, M., McMullen, S., Travis, G.H., and Bok, D. (2011). Complement system dysregulation and inflammation in the retinal pigment epithelium of a mouse model for Stargardt macular degeneration. J. Biol. Chem. *286*, 18593–18601.

Rheaume, B.A., Jereen, A., Bolisetty, M., Sajid, M.S., Yang, Y., Renna, K., Sun, L., Robson, P., and Trakhtenberg, E.F. (2018). Single cell transcriptome profiling of retinal ganglion cells identifies cellular subtypes. Nat. Commun. *9*, 2759.

Roesch, K., Jadhav, A.P., Trimarchi, J.M., Stadler, M.B., Roska, B., Sun, B.B., and Cepko, C.L. (2008). The transcriptome of retinal Müller glial cells. J. Comp. Neurol. *509*, 225–238.

Rose, K.L., Paixao-Cavalcante, D., Fish, J., Manderson, A.P., Malik, T.H., Bygrave, A.E., Lin, T., Sacks, S.H., Walport, M.J., Cook, H.T., et al. (2008). Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice. J. Clin. Invest. *118*, 608–618.

Rutar, M., Natoli, R., Albarracin, R., Valter, K., and Provis, J. (2012). 670-nm light treatment reduces complement propagation following retinal degeneration. J. Neuroinflammation 9, 257.

Schäfer, N., Grosche, A., Reinders, J., Hauck, S.M., Pouw, R.B., Kuijpers, T.W., Wouters, D., Ehrenstein, B., Enzmann, V., Zipfel, P.F., et al. (2016). Complement regulator FHR-3 is elevated either locally or systemically in a selection of autoimmune diseases. Front. Immunol. 7, 542.

Schäfer, N., Grosche, A., Schmitt, S.I., Braunger, B.M., and Pauly, D. (2017). Complement components showed a time-dependent local expression pattern in constant and acute white light-induced photoreceptor damage. Front. Mol. Neurosci. *10*, 197. Scheetz, T.E., Fingert, J.H., Wang, K., Kuehn, M.H., Knudtson, K.L., Alward, W.L.M., Boldt, H.C., Russell, S.R., Folk, J.C., Casavant, T.L., et al. (2013). A genome-wide association study for primary open angle glaucoma and macular degeneration reveals novel loci. PLoS ONE *8*, e58657.

Shekhar, K., Lapan, S.W., Whitney, I.E., Tran, N.M., Macosko, E.Z., Kowalczyk, M., Adiconis, X., Levin, J.Z., Nemesh, J., Goldman, M., et al. (2016). Comprehensive classification of retinal bipolar neurons by single-cell transcriptomics. Cell *166*, 1308–1323.e30.

Silva, P.S., Dela Cruz, A.J., Ledesma, M.G., van Hemert, J., Radwan, A., Cavallerano, J.D., Aiello, L.M., Sun, J.K., and Aiello, L.P. (2015). Diabetic retinopathy severity and peripheral lesions are associated with nonperfusion on ultrawide field angiography. Ophthalmology *122*, 2465–2472.

Sim, R.B., Day, A.J., Moffatt, B.E., and Fontaine, M. (1993). Complement factor I and cofactors in control of complement system convertase enzymes. Methods Enzymol. *223*, 13–35.

Sohn, J.H., Kaplan, H.J., Suk, H.J., Bora, P.S., and Bora, N.S. (2000). Chronic low level complement activation within the eye is controlled by intraocular complement regulatory proteins. Invest. Ophthalmol. Vis. Sci. *41*, 3492–3502.

Sohn, J.-H., Bora, P.S., Suk, H.-J., Molina, H., Kaplan, H.J., and Bora, N.S. (2003). Tolerance is dependent on complement C3 fragment iC3b binding to antigen-presenting cells. Nat. Med. *9*, 206–212.

Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W.M., 3rd, Hao, Y., Stoeckius, M., Smibert, P., and Satija, R. (2019). Comprehensive integration of single-cell data. Cell *177*, 1888–1902.e21.

Sudharsan, R., Beiting, D.P., Aguirre, G.D., and Beltran, W.A. (2017). Involvement of innate immune system in late stages of inherited photoreceptor degeneration. Sci. Rep. 7, 17897.

Tenner, A.J., Stevens, B., and Woodruff, T.M. (2018). New tricks for an ancient system: Physiological and pathological roles of complement in the CNS. Mol. Immunol. *102*, 3–13.

Tian, L., Kazmierkiewicz, K.L., Bowman, A.S., Li, M., Curcio, C.A., and Stambolian, D.E. (2015). Transcriptome of the human retina, retinal pigmented epithelium and choroid. Genomics *105*, 253–264.

Traveset, A., Rubinat, E., Ortega, E., Alcubierre, N., Vazquez, B., Hernández, M., Jurjo, C., Espinet, R., Ezpeleta, J.A., and Mauricio, D. (2016). Lower hemoglobin concentration is associated with retinal ischemia and the severity of diabetic retinopathy in type 2 diabetes. J. Diabetes Res. *2016*, 3674946.

Wagner, L., Pannicke, T., Frommherz, I., Sauer, K., Chen, J., and Grosche, A. (2016). Effects of IP3R2 receptor deletion in the ischemic mouse retina. Neurochem. Res. *41*, 677–686.

Wagner, L., Pannicke, T., Rupprecht, V., Frommherz, I., Volz, C., Illes, P., Hirrlinger, J., Jägle, H., Egger, V., Haydon, P.G., et al. (2017). Suppression of SNARE-dependent exocytosis in retinal glial cells and its effect on ischemiainduced neurodegeneration. Glia *65*, 1059–1071.

Walker, D.G., and McGeer, P.L. (1992). Complement gene expression in human brain: comparison between normal and Alzheimer disease cases. Brain Res. Mol. Brain Res. *14*, 109–116.

Wang, J., Yang, M.M., Li, Y.B., Liu, G.D., Teng, Y., and Liu, X.M. (2013). Association of CFH and CFB gene polymorphisms with retinopathy in type 2 diabetic patients. Mediators Inflamm. *2013*, 748435.

Weber, B.H.F., Charbel Issa, P., Pauly, D., Herrmann, P., Grassmann, F., and Holz, F.G. (2014). The role of the complement system in age-related macular degeneration. Dtsch. Arztebl. Int. *111*, 133–138.

Yang, M.M., Wang, J., Ren, H., Sun, Y.D., Fan, J.J., Teng, Y., and Li, Y.B. (2016). genetic investigation of complement pathway genes in type 2 diabetic retinopathy: an inflammatory perspective. Mediators Inflamm. 2016, 1313027.

Zhang, J., Gerhardinger, C., and Lorenzi, M. (2002). Early complement activation and decreased levels of glycosylphosphatidylinositol-anchored complement inhibitors in human and experimental diabetic retinopathy. Diabetes *51*, 3499–3504.

STAR***METHODS**

KEY RESOURCES TABLE

nouse anti-CD29-Blotin Mitteny Biotec (Bergisch-Gladbach, Germany) 130-101-943; RRID:AB_2660700 abbit anti-FDHB Abcam (Cambridge, UK) ab15996; RRID:AB_2814826 abbit anti-C1s Proteintech (Rosemont, IL, USA) #14554-1.4P/ (Schafer et al., 2017); RRID:AB_2814827 apat anti-C4 Complement Technologies (Tyler, TX, USA) #A25; RRID:AB_2814828 apat anti-C3 Abcam (Cambridge, UK) #31187; RRID:AB_2814828 apat anti-C4 Complement Technologies (Tyler, TX, USA) #425; RRID:AB_2814828 apat anti-C5 Quidel (San Diego, CA, USA) #55577 (Schäfer et al., 2017); RRID:AB_2082392 apat anti-CFB Merck (Darmstadt, Germany) #341272 / (Schäfer et al., 2017); RRID:AB_2084382 apat anti-C5 Quidel (San Diego, CA, USA) #4237; RRID:AB_263484 opat anti-C6 Complement Technologies (Tyler, TX, USA) #42817; RRID:AB_2814832 apat anti-C7 Tecomodical (Sissach, CH) #4308; RRID:AB_2814833 at anti-C7P in-house (Schäfer et al., 2017) apat anti-C7 Antioodies (Alexen, Germany) #31276; RRID:AB_2814833 at anti-C7P in-house (Schäfer et al., 2017); apat anti-C7P Merck	REAGENT or RESOURCE	SOURCE	IDENTIFIER	
Germany Complement abbit anti-C1s Proteintech (Rosemont, IL, USA) #14554-1-AP / (Schäfer et al., 2017); RTID:AB_2814827 poat anti-C3 Complement Technologies (Tyler, TX, USA) #25557 / Schäfer et al., 2017) poat anti-C3 Abcam (Cambridge, UK) ab11807; RRID:AB_2814827 poat anti-C3 Abcam (Cambridge, UK) ab11807; RRID:AB_280669 poat anti-C5 Quidal (San Diego, CA, USA) #241727; (Schäfer et al., 2017); poat anti-C5 Quidal (San Diego, CA, USA) #24217; RRID:AB_2814821 poat anti-C5 Quidal (San Diego, CA, USA) #24217; RRID:AB_2814832 poat anti-C6 Complement Technologies (Tyler, TX, USA) #223; RRID:AB_2814832 poat anti-C7 Tecomedical (Sasach, CH) #A308; RRID:AB_2814832 poat anti-C7 Tecomedical (Sasach, CH) #31276; RRID:AB_2814833 poat anti-C7 Tecomedical (Sasach, CH) #3317 (Frices et al., 2017) poat anti-C7 Wako Chemicals (News, Germany) #31174714; RRID:AB_2814833 poat anti-C7 Wako Chemicals (News, Germany) #301371 (Schäfer et al., 2016); RRID:AB_212514 abit anti-BA1 Wako Chemicals (Germany) #3014176: Schäfer et al., 2016);	Antibodies			
abbit anti-C1s Proteintech (Rosemont, IL, USA) #14554-1-AP / (Schafter et al., 2017); RRID-AB_2814827 Apat anti-C4 Complement Technologies (Tyler, TX, USA) #25557 / (Schafter et al., 2017); RRID-AB_2814827 Apat anti-C3 Abcam (Cammada (Santa Ana, CA, USA) #55557 / (Schafter et al., 2017); RRID-AB_2814828 abbit anti-C3 Abcam (Cammada (Santa Ana, CA, USA) #55557 / (Schafter et al., 2017); RRID-AB_2814828 abbit anti-C5 Murck (Darmstadt, Germany) #341227 (Schafter et al., 2017); RRID-AB_2814831 Abcam (Cammada (Santa Ana, CA, USA) #475430; RRID-AB_2814831 anti-C7 RRID-AB_2814832 abbit anti-C6 Complement Technologies (Tyler, TX, USA) #4217, RRID-AB_2814832 abbit anti-C6 Complement Technologies (Tyler, TX, USA) #4217, RRID-AB_2814832 abbit anti-C6 Antibodies online (Aachen, Germany) #4211276; RRID-AB_2814832 abbit anti-C7P In-house (Schäfer et al., 2017) poat anti-C7P in-house (Schäfer et al., 2017) poat anti-C7P Aution (Gammada (Germany) #341276; RRID-AB_2814832 abbit anti-BA1 Wako Chemicals (Neuse, Germany) #019-19741 / (Schäfer et al., 2016); RRID-AB_839504 mouse anti-glutamine sythetase Merck (Darmstadt, Germany) #019-19741 / Schäfer 2012, 2003; RRID-AB_238128 abbit anti-BA1 Wako Chemicals (Neuse, Germany) #019-205-003; RRID-AB_238128 abbit anti-BA1 Wako Chemicals (Germany) #111-035-003; RRID-AB_238128 Arbit anti-abbit (g-HRP Dianova (Hamburg, Germany) #111-035-003; RRID-AB_2338128 Dianova (Hamburg, Germany) #111-035-003; RRID-AB_2338129 Dianova (Hamburg, Germany) #111-035-003; RRID-AB_2338129 Dianova (Hamburg, Germany) #110-035-003; RRID-AB_2338129 Dianova (Ha	nouse anti-CD29-Biotin		130-101-943; RRID:AB_2660700	
RRID-AB_2814827 RRID-AB_2814827 peat anti-C24 Complement Technologies (Tyler, TX, USA) #A205; RRID-AB_2814828 peat anti-C3 Abcam (Cambridge, UK) ab11887; RRID-AB_298669 abbit anti-C4 Merck (Darmstadt, Germany) #341272 (Schäfer et al., 2017), RRID-AB_208232 heep anti-C7D RRD Systems (Mineapolis, MN, USA) #A253; RRID-AB_452484 pat anti-C3 Quidel (San Diego, CA, USA) #A217; RRID-AB_214832 pat anti-C6 Complement Technologies (Tyler, TX, USA) #A223; RRID-AB_214831 pat anti-C7 Tecomedical (Sissach, CH) #A308; RRID-AB_214832 pat anti-C7 Tecomedical (Sissach, CH) #A308; RRID-AB_214833 pat anti-C7 Tecomedical (Sissach, CH) #A308; RRID-AB_214833 pat anti-C7F Minbodies online (Aachen, Germany) #341276; RRID-AB_2814833 pat anti-C7F Quidel (San Diego, CA, USA) A313 (Toese et al., 2017) pat anti-C7F Quidel (San Diego, CA, USA) A312 (Toese et al., 2018); RRID-AB_452514 abbit anti-G8 Merck (Darmstadt, Germany) #31276; RRID-AB_238128 mouse anti-glutamine synthetase Merck (Darmstadt, Germany) #11-035-003; RRID-AB_238128	abbit anti-PDHB	Abcam (Cambridge, UK)	ab155996; RRID:AB_2814826	
poat anti-C3-HRP MP Biomedicals (Santa Ana, CA, USA) #55557 / (Schäfer et al., 2017) abbit anti-C3 Abcam (Cambridge, UK) ab11887; RRIDAB_298669 poat anti-CFB Merck (Darmstadt, Germany) #41272 / (Schäfer et al., 2017); RRIDAB_2082382 heep anti-CFD R&D Systems (Minneapolis, MN, USA) #AF5430; RRIDAB_1655866 nouse anti-C5 Quidel (San Diego, CA, USA) #A217; RIDAB_452484 poat anti-C6 Complement Technologies (Tyler, TX, USA) #A217; RIDAB_452484 abbit anti-C6 Complement Technologies (Tyler, TX, USA) #A217; RIDAB_2814832 abbit anti-C7 Tecomedical (Sissach, CH) #A308; RRIDAB_2814833 at anti-C7 Tecomedical (Sissach, CH) #A308; RRIDAB_2814833 poat anti-CFH Merck (Darmstadt, Germany) #A1276; RRIDAB_2080303 poat anti-CFH Quidel (San Diego, CA, USA) A313 / (Rose et al., 2009); RRIDAB_281260 poat anti-CFH Quidel (San Diego, CA, USA) A313 / (Rose et al., 2019); RRIDAB_23186 nouse anti-glutamine sythetase Merck (Darmstadt, Germany) #A12035.003; RRIDAB_2338128 poat anti-cbit Ig-HRP Dianova (Hamburg, Germany) #110-35-003; RRIDAB2338128 pata anti-abbit Ig-HRP Dianova (Hamburg, Germany) #110-35-003; RRIDAB2339400 pata anti-abbit Ig-HRP Dianova (Hamburg, Germany) #10520; RRIDAB2339400	abbit anti-C1s	Proteintech (Rosemont, IL, USA)		
abbit anti-C3 Abcam (Cambridge, UK) ab11887; RRID:AB_298669 opat anti-CFE Merck (Darmstadt, Germany) #341272 (/Schäfer et al., 2017); RRID:AB_2082392 wheep anti-CFD R&D Systems (Minneapolis, MN, USA) #AF430; RRID:AB_1655868 nouse anti-C5 Quidel (San Diego, CA, USA) #A217; RRID:AB_2814831 opat anti-C6 Complement Technologies (Tyler, TX, USA) #A223; RRID:AB_2814832 abbit anti-C7 Tecomedical (Sissach, CH) #A308; RRID:AB_2814832 abbit anti-C9 Antibodies online (Aachen, Germany) #AB11714714; RRID:AB_2814833 at anti-CFP in-house (Schäfer et al., 2017) opat anti-CFH Merck (Darmstadt, Germany) #341276; RRID:AB_2814833 abbit anti-GP Quidel (San Diego, CA, USA) A313 / (Rose et al., 2008); RRID:AB_452514 abbit anti-GP Quidel (San Diego, CA, USA) A313 / (Rose et al., 2017) poat anti-CFH Quidel (Carmstadt, Germany) #019-18741 / (Schäfer et al., 2016); RRID:AB_35504 nouse anti-glutamine sythetase Merck (Darmstadt, Germany) #111-035-003; RRID:AB_21398128 ababit anti-GP Dianova (Hamburg, Germany) #111-035-003; RRID:AB2313567 ababit anti-goal (g-HRP) Dianova (Hamburg, Germany) #305-035-003; RRID:AB2339400 abat anti-goal (g-HRP) Dianova (Hamburg, Germany) #30-035-033; RRID:AB2339400 </td <td>joat anti-C4</td> <td>Complement Technologies (Tyler, TX, USA)</td> <td>#A205; RRID:AB_2814828</td>	joat anti-C4	Complement Technologies (Tyler, TX, USA)	#A205; RRID:AB_2814828	
peat anti-CFB Merck (Darmstadt, Germany) #341272 / (Schäfer et al., 2017); RRID:AB_2082392 heep anti-CFD R&D Systems (Minneapolis, MN, USA) #AF5430; RRID:AB_1655868 nouse anti-C5 Quidei (San Diego, CA, USA) #A217; RRID:AB_452484 (got anti-C6 Complement Technologies (Tyler, TX, USA) #A223; RRID:AB_452484 (got anti-C7 Tecomedical (Sissach, CH) #A308; RRID:AB_2814832 abbit anti-C7 Tecomedical (Sissach, CH) #A308; RRID:AB_2814832 abbit anti-C7 Tecomedical (Sissach, CH) #A308; RRID:AB_2814832 abbit anti-C7P in-house (Schäfer et al., 2017) (got anti-CFH Merck (Darmstadt, Germany) #341276; RRID:AB_2814833 (got anti-CFH Quidei (San Diego, CA, USA) A313 / (Rose al., 2008); RRID:AB_452514 abbit anti-IBA1 Wako Chemicals (Neuss, Germany) #019-1974 1 / (Schäfer et al., 2017) (got anti-CFI Quidei (San Diego, CA, USA) A313 / (Rose al., 2009); RRID:AB_2519; RRID:AB_239504 nouse anti-glutamine sythetase Merck (Darmstadt, Germany) #019-1974 1 / (Schäfer et al., 2019); RRID:AB_839504 nouse anti-glutamine sythetase Merck (Darmstadt, Germany) #111-035-003; RRID:AB_2338128 (got anti-rabbit Ig-HRP Dianova (Hamburg, Germany) #111-035-003; RRID:AB2339400 (got anti-rabbit Ig-HRP Dianova (Hamburg, Germany) #110-035-003; RRID:AB2339400 (got anti-rabbit Ig-HRP Dianova (Hamburg, Germany) #110-035-003; RRID:AB2339400 (got anti-rabbit Ig-HRP Dianova (Hamburg, Germany) #105-035-003; RRID:AB2339400 (got anti-rabbit Ig-HRP Dianova (Hamburg, Germany) #110-035-003; RRID:AB2339400 (got anti-rabbit Ig-HRP Dianova (Hamburg, Germany) #110-035-003; RRID:AB2339400 (got anti-rabbit Ig-HRP Dianova (Hamburg, Germany) #110-035-003; RRID:AB2339400 (got anti-got Ig-HRP Dianova (Hamburg, Germany) #120-035-003; RRID:AB2339400 (got anti-got Ig-HRP Dianova (Ham	joat anti-C3-HRP	MP Biomedicals (Santa Ana, CA, USA)	#55557 / (Schäfer et al., 2017)	
heep anti-CFD R&D Systems (Minneapolis, MN, USA) #AF5430; RRID:AB_1655868 nouse anti-C5 Quidel (San Diego, CA, USA) #217; RRID:AB_452444 Complement Technologies (Tyler, TX, USA) #A223; RRID:AB_2814831 recommendial (Sissach, CH) #3208; RRID:AB_2814832 abbit anti-C7 Tecomedical (Sissach, CH) #3208; RRID:AB_2814832 abbit anti-C9 Antibodies online (Aachen, Germany) #ABIN1714714; RRID:AB_2814833 at anti-CFP in-house (Schäfer et al., 2017) goat anti-CFI Quidel (San Diego, CA, USA) A313 / (Fose et al., 2009): RRID:AB_452514 abbit anti-CFI Quidel (San Diego, CA, USA) A313 / (Fose et al., 2009): RRID:AB_452514 abbit anti-HBA1 Wako Chemicals (Neuss, Germany) #019-19741 / (Schäfer et al., 2016); RRID:AB_389504 mouse anti-glutamine sythetase Merck (Darmstadt, Germany) #112-035-003; RRID:AB_2338128 poat anti-CFI Dianova (Hamburg, Germany) #112-035-003; RRID:AB_2338128 poat anti-rat Ig-HRP Dianova (Hamburg, Germany) #111-035-003; RRID:AB_2338128 poat anti-rat Ig-HRP Dianova (Hamburg, Germany) #111-035-003; RRID:AB_2338128 poat anti-rabbit Ig-HRP Dianova (Hamburg, Germany) #305-035-003; RRID:AB_2338128 poat anti-rabbit Ig-HRP Dianova (Hamburg, Germany) #305-035-003; RRID:AB_2338128 poat anti-rabbit Ig-HRP Dianova (Hamburg, Germany) #310-035-003; RRID:AB_2338128 poat anti-rabbit Ig-HRP Dianova (Hamburg, Germany) #305-035-003; RRID:AB_2338128 poat anti-rabbit Ig-HRP Dianova (Hamburg, Germany) #305-035-003; RRID:AB_233400 poat anti-rabbit Ig-HRP Dianova (Hamburg, Germany) #305-035-003; RRID:AB_233400 poat anti-rabbit Ig-HRP Dianova (Hamburg, Germany) #310-035-003; RRID:AB_233402 poat anti-rabbit Ig-HRP Dianova (Hamburg, Germany) #305-035-003; RRID:AB_233402 poat anti-rabbit Ig-HRP Mitery Biotec 130-097-418 portical Commercial Assay prevential Models: Organisms/Strains prevential Models: Organisms/Strains preven	abbit anti-C3	Abcam (Cambridge, UK)	ab11887; RRID:AB_298669	
mouse anti-C5 Quidel (San Diego, CA, USA) #A217; RRID:AB_452484 poat anti-C6 Complement Technologies (Tyler, TX, USA) #A223; RRID:AB_2814831 joat anti-C7 Tecomedical (Sissach, CH) #A308; RRID:AB_2814833 at anti-CFP in-house (Schäfer et al., 2017) joat anti-CFH Merck (Darmstadt, Germany) #34127; RRID:AB_2080303 joat anti-Balt Wako Chemicals (Neuss, Germany) #315 (Goea et al., 2019); RRID:AB_2110656 joat anti-rabit g-HRP Dianova (Hamburg, Germany) #112-035-003; RRID:AB_2338128 joat anti-rabit ig-HRP Dianova (Hamburg, Germany) #3105:085-003; RRID:AB_2338400 joat anti-rabit ig-HRP Dianova (Hamburg, Germany) #3105:085-003; RRID:AB_2338400 joat anti-rabit ig-HRP Dianova (Hamburg, Germany) #3105:003; RRID:AB_2338400 joat anti-rabit ig-Groupaides, human Milteny Bi	goat anti-CFB	Merck (Darmstadt, Germany)	#341272 / (Schäfer et al., 2017); RRID:AB_2082392	
poat anti-C66 Complement Technologies (Tyler, TX, USA) #A223; RRID:AB_2814831 poat anti-C7 Tecomedical (Sissach, CH) #A08, RRID:AB_2814832 abbit anti-C9 Antibodies online (Aachen, Germany) #ABIN171141; RRID:AB_2814833 at anti-CFP in-house (Schäfer et al., 2017) poat anti-CFH Merck (Darmstadt, Germany) #341276; RRID:AB_2080303 poat anti-CFH Merck (Darmstadt, Germany) #341276; RRID:AB_2080303 poat anti-CFH Quidel (San Diego, CA, USA) A313 (Nose et al., 2008); RRID:AB_452514 abbit anti-GFH Quidel (San Diego, CA, USA) A313 (Nose et al., 2016); RRID:AB_452504 abbit anti-BA1 Wako Chemicals (Neuss, Germany) #101-037-003; RRID:AB_452514 poat anti-JBA1 Wako Chemicals (Neuss, Germany) #112-035-003; RRID:AB_23804 nouse anti-glutamine sythetase Merck (Darmstadt, Germany) #111-035-003; RRID:AB_2338128 poat anti-Jabbit 1g-HRP Dianova (Hamburg, Germany) #111-035-003; RRID:AB_2339400 poat anti-rabbit-IG-Cy3 ThermoFisher (Braunschweig, Germany) #10520; RRID:AB2354029 chemicals, Peptides, and Recombinant Proteins D11h (MicroBeads, human Milteny Biotec 130-093-634 and mouse Milteny Biotec 130-097-418 Anti-Biotin MicroBeads (JuraPure Milteny Biotec 130-105-637 Critical Commercial Assays ThermoFisher Scientific X1632 Synthesis Kit TureLink® RNA Micro Scale Kit Thermo Fisher Scientific X1632 Synthesis Kit TureLink® RNA Micro Scale Kit Thermo Fisher Scientific X1632 Sperimental Models: Organisms/Strains ALB/CJR] mice Janvier Labs SC-BALBJ-M 257BL/GJ Jackson Laboratories 000664 Digonucleotides Experimental Models: Organisms/Strains Stalb/CJR] mice Janvier Labs SC-BALBJ-M 257BL/GJ Jackson Laboratories 000664 Digonucleotides Experimental Models: Organisms/Strains Sc-BALBJ-M Software and Algorithms Troegenesis OI software for proteomics Nonlinear Dynamics, Waters, New Castel upon Tyne, U.K.	heep anti-CFD	R&D Systems (Minneapolis, MN, USA)	#AF5430; RRID:AB_1655868	
Tecomedical (Sissach, CH)#A308; RRID:AB_2814832abbit anti-C9Antibodies online (Aachen, Germany)#ASINT14714; RRID:AB_2814833at anti-CFPin-house(Schäfer et al., 2017)poat anti-CFHMerck (Darmstadt, Germany)#341276; RRID:AB_2080303abbit anti-IBA1Wako Chemicals (Neuss, Germany)#31976; RRID:AB_2080303poat anti-CFHQuidel (San Diego, CA, USA)A313 (Rose et al., 2008); RRID:AB_452514abbit anti-IBA1Wako Chemicals (Neuss, Germany)#019-19741 / (Schäfer et al., 2016); RRID:AB_839504nouse anti-glutamine sythetaseMerck (Darmstadt, Germany)#112-035-003; RRID:AB_2338128poat anti-rabit Ig-HRPDianova (Hamburg, Germany)#111-035-003; RRID:AB_2338128poat anti-rabit Ig-HRPDianova (Hamburg, Germany)#110-035-003; RRID:AB_2339400poat anti-rabit Ig-HRPDianova (Hamburg, Germany)#110-035-003; RRID:AB2339400poat anti-rabit-Id-Cy3ThermoFisher (Braunschweig, Germany)#110-205abbit anti-goat Ig-HRPDianova (Hamburg, Germany)#30520D116 (Microglia) MicroBeads, humanMilteny Biotec130-097-418and mouse2011 MicroBeads, nouseMilteny Biotec130-097-4182011 MicroBeads, mouseMilteny Biotec130-105-6372012 MicroBeads UltraPureMilteny Elotec130-105-6372013 MicroBeads UltraPureMilteny Elotec121830162024 DataGene Expression Onnibus (GEO)GSE1164262030 MicroBeads UltraPureJanvier LabsSC-BALBJ-M2051 MicroBeadsJanvier Labs	nouse anti-C5	Quidel (San Diego, CA, USA)	#A217; RRID:AB_452484	
abbit anti-C9Antibodies online (Aachen, Germany)#ABIN1714714; RRID:AB_2814833at anti-CFPin-house(Schäfer et al., 2017)peat anti-CFHMerck (Darmstadt, Germany)#341276; RRID:AB_2080303poat anti-CFIQuidel (San Diego, CA, USA)A313 / (Rose et al., 2009); RRID:AB_452514abbit anti-IBA1Wako Chemicals (Neuss, Germany)#019-19741 / (Schäfer et al., 2016); RRID:AB_452514mouse anti-glutamine sythetaseMerck (Darmstadt, Germany)#112-035-003; RRID:AB_2318267poat anti-rat Ig-HRPDianova (Hamburg, Germany)#112-035-003; RRID:AB_2338128poat anti-rabbit Ig-HRPDianova (Hamburg, Germany)#305-035-033; RRID:AB_23381267poat anti-rabbit Ig-HRPDianova (Hamburg, Germany)#305-035-033; RRID:AB_2338126poat anti-rabbit Ig-HRPDianova (Hamburg, Germany)#305-035-033; RRID:AB_2338400poat anti-rabbit Ig-HRPDianova (Hamburg, Germany)#305-035-037; RRID:AB_2338400poat anti-rabbit Ig-HRPDianova (Hamburg, Germany)#305-035-037; RRID:AB_2338400poat anti-rabbit Ig-HRPDianova (Hamburg, Germany)#305-035, RRID:AB2339400poat anti-rabbit Ig-HRPDianova (Hamburg, Germany)#305-035; RRID:AB2_2338400poat anti-GCGThermoFisher (Braunschweig, Germany)#30-037poat anti-GL Cy3ThermoFisher (Braunschweig, Germany)#30-037poat anti-GL Cy3Milteny Biotec130-097-418poat anti-GL Cy3ThermoFisher Scientific12183016poat anti-GL MangarGene Expression Onnibus (GEO)GSE116426poat anti-GL Masay	joat anti-C6	Complement Technologies (Tyler, TX, USA)	#A223; RRID:AB_2814831	
at anti-CFP in-house (Schäfer et al., 2017) apat anti-CFH Merck (Darmstadt, Germany) #341276; RRID:AB_2080303 (Joat anti-CFH Quidel (San Diego, CA, USA) A313 (Fose et al., 2009): RRID:AB_452514 abbit anti-IBA1 Wako Chemicals (Neuss, Germany) #019-19741/ (Schäfer et al., 2016); RRID:AB_39504 house anti-glutamine sythetase Merck (Darmstadt, Germany) #112-035-003; RRID:AB_2110656 (Joat anti-ratig-HRP Dianova (Hamburg, Germany) #112-035-003; RRID:AB_231367 abbit anti-gabit Ig-HRP Dianova (Hamburg, Germany) #111-035-003; RRID:AB_2338128 Joat anti-rabbit Ig-HRP Dianova (Hamburg, Germany) #305-035-003; RRID:AB233960 Joat anti-rabbit Ig-GY3 ThermoFisher (Braunschweig, Germany) #305-035-003; RRID:AB2339400 Joat anti-rabbit Ig-GY3 ThermoFisher (Braunschweig, Germany) #410520; RRID:AB2339400 Joat anti-rabbit Ig-GY3 ThermoFisher (Braunschweig, Germany) #305-035-003; RRID:AB239400 Joat anti-rabbit Ig-GY3 ThermoFisher Scientific 130-097-418 Nufi-Biotim MicroBeads, human in Milteny Biotec 130-097-418 Nufi-Biotim MicroBeads UltraPure Milteny Eister Scientific 12183016 Joeposited Data CERVA sequencing data Gene Expression Omnibus (GEO) GSE116426 Experimental Models: Organisms/Strains JALE/GAJ Jackson Laboratories 000664 Jigonucleotides ee Table S6 This paper N/A Software and Algorithms Yogenesis QI software for proteomics Version 3.0) Nollinear Dynamics, Waters, N/A V/A	joat anti-C7	Tecomedical (Sissach, CH)	#A308; RRID:AB_2814832	
joat anti-CFH Merck (Darmstadt, Germany) #341276; RRID:AB_2080303 joat anti-CFI Quidel (San Diego, CA, USA) A313 / (Rose et al., 2008); RRID:AB_452514 abbit anti-IBA1 Wako Chemicals (Neuss, Germany) #019-19741 / (Schäfer et al., 2016); RRID:AB_839504 nouse anti-glutamine sythetase Merck (Darmstadt, Germany) MAB302 /(Mages et al., 2019); RRID:AB_2110656 joat anti-rat lg-HRP Dianova (Hamburg, Germany) #111-035-003; RRID:AB_2338128 to at anti-rabbit lg-HRP Dianova (Hamburg, Germany) #111-035-003; RRID:AB_2338128 pat anti-rabbit lg-HRP Dianova (Hamburg, Germany) #305-035-003; RRID:AB2339400 joat anti-rabbit lg-HRP Dianova (Hamburg, Germany) #305-035-003; RRID:AB2339400 joat anti-rabbit l-G-Cy3 ThermoFisher (Braunschweig, Germany) #10520; RRID:AB2339400 joat anti-rabbit lg-HRP Dianova (Hamburg, Germany) #305-035-003; RRID:AB2334029 Dhemicals, Peptides, and Recombinant Proteins 2D11b (MicroBeads, human Milteny Biotec 130-097-418 milt-Biotin MicroBeads, IltraPure Milteny Biotec 130-105-637 Critical Commercial Assays RevertAid H Minus First-Strand cDNA Thermo Fisher Scientific 12183016 PureLink® RNA Micro Scale Kit Thermo Fisher Scientific 12183016 PureLink® RNA Micro Scale Kit Thermo Fisher Scientific 12183016 Experimental Models: Organisms/Strains 3ALB/cJR] mice Janvier Labs SC-BALBJ-M 257BL/cJ Jackson Laboratories 000664 J[]gonucleotides me Table S6 This paper N/A Software and Algorithms Progenesis OI software for proteomics Version 3.0) Nonlinear Dynamics, Waters, Naters, N/A N/A	abbit anti-C9	Antibodies online (Aachen, Germany)	#ABIN1714714; RRID:AB_2814833	
opta anti-CFIQuidel (San Diego, CA, USA)A313 / (Rose et al., 2008): RRID:AB_452514abbit anti-IBA1Wako Chemicals (Neuss, Germany)#019-1974 / (Schäfer et al., 2016); RRID:AB_839504nouse anti-glutamine sythetaseMerck (Darmstadt, Germany)MA8302 /(Mages et al., 2019); RRID:AB_2338128joat anti-rat lg-HRPDianova (Hamburg, Germany)#112-035-003; RRID:AB_2338128joat anti-rabbit lg-HRPDianova (Hamburg, Germany)#305-035-003; RRID:AB_2339400joat anti-rabbit-IG-Cy3ThermoFisher (Braunschweig, Germany)#305-035-003; RRID:AB2534029Zhemicals, Peptides, and Recombinant ProteinsZonogra-6342D11b (Microglia) MicroBeads, humanMilteny Biotec130-097-418Anti-Biotin MicroBeads, nouseMilteny Biotec130-097-418Anti-Biotin MicroBeads UltraPureMilteny Biotec130-105-637Zhrital Commercial AssaysThermo Fisher ScientificK1632PureLink@ RNA Micro Scale KitThermo Fisher Scientific12183016PureLink@ RNA Micro Scale KitThermo Fisher Scientific12183016ZoponismerJohatGene Expression Onnibus (GEO)GSE116426Experimental Models: Organisms/StrainsJackson LaboratoriesSO-064JilgonucleotidesJackson LaboratoriesN/ASoftware and AlgorithmsNonlinear Dynamics, Waters, Tyre, U.K.N/A	at anti-CFP	in-house	(Schäfer et al., 2017)	
poat anti-CFIQuidel (San Diego, CA, USA)A313 / (Rose et al., 2008): RRID:AB_452514abbit anti-IBA1Wako Chemicals (Neuss, Germany)#019-1974 / (Schäfer et al., 2016); RRID:AB_839504nouse anti-glutamine sythetaseMerck (Darmstadt, Germany)MAB302 /(Mages et al., 2019); RRID:AB_2310656goat anti-rat Ig-HRPDianova (Hamburg, Germany)#112-035-003; RRID:AB_2338128goat anti-rabbit Ig-HRPDianova (Hamburg, Germany)#305-035-003; RRID:AB2339400goat anti-rabbit-G-Cy3ThermoFisher (Braunschweig, Germany)#305-035-003; RRID:AB2339400poat anti-rabbit-G-Cy3ThermoFisher (Braunschweig, Germany)#305-035-003; RRID:AB2334029Dhemicals, Peptides, and Recombinant ProteinsDianova (Hamburg, Germany)#3105-037-032; RRID:AB23340292D11b (MicroBeads, human Milteny Biotec130-097-418MIAnti-Biotin MicroBeads, Muman Milteny Biotec130-097-418MIAnti-Biotin MicroBeads, Muran Milteny Biotec130-097-418MIAnti-Biotin MicroBeads UltraPure Milteny Biotec130-097-418MIAnti-Biotin MicroBeads UltraPure Milteny Biotec130-105-637MIPureLink® RNA Micro Scale Kit Thermo Fisher ScientificK1632MIPureLink® RNA Micro Scale KitThermo Fisher Scientific12183016Poposited DataSc-BALBJ-MSc-BALBJ-MSZPBL/GJJackson LaboratoriesSC-BALBJ-MSZPBL/GJJackson LaboratoriesSC-BALBJ-MSZPBL/GJJackson LaboratoriesSC-BALBJ-MSoftware and AlgorithmsNonlinear Dynamics, Wat	joat anti-CFH	Merck (Darmstadt, Germany)	#341276; RRID:AB_2080303	
NumberRRID:AB_839504nouse anti-glutamine sythetaseMerck (Darmstadt, Germany)MAB302 /(Mages et al., 2019); RRID:AB_2110656joat anti-rat Ig-HRPDianova (Hamburg, Germany)#112-035-003; RRID:AB_2338128joat anti-rabbit Ig-HRPDianova (Hamburg, Germany)#111-035-003; RRID:AB_2339400joat anti-rabbit Ig-HRPDianova (Hamburg, Germany)#305-035-035; RRID:AB2339400joat anti-rabbit-IG-Cy3ThermoFisher (Braunschweig, Germany)#A10520; RRID:AB2339400joat anti-rabbit-IG-Cy3ThermoFisher (Braunschweig, Germany)#A10520; RRID:AB2339400joat anti-rabbit-IG-Cy3ThermoFisher (Braunschweig, Germany)#A10520; RRID:AB2339400joat anti-rabbit-IG-Cy3ThermoFisher (Braunschweig, Germany)#A10520; RRID:AB2339400joat anti-rabbit-IG-Cy3Milteny Biotec130-097-418commercial, SpantorMilteny Biotec130-097-418ind mouseMilteny Biotec130-097-418ind inoroBeads, museMilteny Biotec130-097-418ind inoroBeads UltraPureMilteny Biotec130-097-418int-Biotin MicroBeads UltraPureMilteny Biotec130-097-418intervertAid H Minus First-Strand cDNAThermo Fisher ScientificK1632synthesis KitThermo Fisher Scientific12183016ureLink@ RNA Micro Scale KitThermo Fisher Scientific12183016Deposited DataGene Expression Omnibus (GEO)GSE116426icsperimental Models: Organisms/StrainsJackson Laboratories000664257BL/6JJackson Laboratories000664Oligo		Quidel (San Diego, CA, USA)	A313 / (Rose et al., 2008): RRID:AB_452514	
joat anti-rat Ig-HRP Dianova (Hamburg, Germany) #112-035-003; RRID:AB_2338128 joat anti-rabbit Ig-HRP Dianova (Hamburg, Germany) #111-035-003; RRID:AB2313567 abbit anti-goat Ig-HRP Dianova (Hamburg, Germany) #305-035-003; RRID:AB2339400 joat anti-rabbit-IG-Cy3 ThermoFisher (Braunschweig, Germany) #A10520; RRID:AB2339400 Demicals, Peptides, and Recombinant Proteins 2D11h (Microglia) MicroBeads, human Milteny Biotec 130-093-634 mod mouse Milteny Biotec 130-093-634 Milteny Biotec 130-097-418 Milteny Biote	abbit anti-IBA1	Wako Chemicals (Neuss, Germany)		
Joad anti-rabbit Ig-HRPDianova (Hamburg, Germany)#111-035-003; RRID:AB2313667abbit anti-goat Ig-HRPDianova (Hamburg, Germany)#305-035-003; RRID:AB2339400Joad anti-rabbit-IG-Cy3ThermoFisher (Braunschweig, Germany)#A10520; RRID:AB2534029Chemicals, Peptides, and Recombinant Proteins#A10500; RRID:AB2534029Chemicals, Peptides, and Recombinant Proteins130-093-634CD11b (MicroBeads, human and mouseMilteny Biotec130-097-418D31 MicroBeads, mouseMilteny Biotec130-097-418Chemical AssaysMilteny Biotec130-105-637SeverAid H Minus First-Strand cDNA Synthesis KitThermo Fisher ScientificK1632Ortical Commercial AssaysThermo Fisher Scientific12183016PureLink® RNA Micro Scale KitThermo Fisher Scientific12183016PureLink® RNA Micro Scale KitGene Expression Omnibus (GEO)GSE116426Staperimental Models: Organisms/StrainsSC-BALBJ-MSALB/cJRJ miceJanvier LabsSC-BALBJ-MS57BL/6JJackson Laboratories000664OligonucleotidesInis paperN/ASoftware and AlgorithmsNonlinear Dynamics, Waters, Newcastle upon Tyne, U.K.N/A	nouse anti-glutamine sythetase	Merck (Darmstadt, Germany)	MAB302 /(Mages et al., 2019); RRID:AB_2110656	
abbit anti-goat Ig-HRPDianova (Hamburg, Germany)#305-035-003; RRID:AB233400oat anti-rabbit-IG-Cy3ThermoFisher (Braunschweig, Germany)#A10520; RRID:AB2534029chemicals, Peptides, and Recombinant ProteinsStatumer (Interpreteins)2D11b (Microglia) MicroBeads, human nd mouseMilteny Biotec130-093-634chemicals, NeuseMilteny Biotec130-097-418chevrita (Interpreteins)Milteny Biotec130-105-637chevrita (Interpreteins)Milteny Biotec130-105-637chevrita (Interpreteins)Thermo Fisher ScientificK1632chevrita (Interpreteins)Thermo Fisher Scientific12183016tevertAid H Minus First-Strand cDNA ynthesis KitThermo Fisher Scientific12183016tevertAid H Moles: Organisms/StrainsGene Expression Omnibus (GEO)GSE116426chevrita (Interpreteins)Janvier LabsSC-BALBJ-Mchevrita (Interpreteins)Jackson Laboratories000664VilgonucleotidesThis paperN/Acerta and AlgorithmsFinis paperN/Arogenesis QI software for proteomics (arsion 3.0)Nonlinear Dynamics, Waters, Newcastle upon Tyne, U.K.N/A	oat anti-rat Ig-HRP	Dianova (Hamburg, Germany)	#112-035-003; RRID:AB_2338128	
oot anti-rabbit-IG-Cy3ThermoFisher (Braunschweig, Germany)#A10520; RRID:AB2534029chemicals, Peptides, and Recombinant Proteins130-093-634cD11b (Microglia) MicroBeads, human nd mouseMilteny Biotec130-097-418cD31 MicroBeads, mouseMilteny Biotec130-097-418cD31 MicroBeads UltraPureMilteny Biotec130-097-418contractical Commercial AssaysHermo Fisher ScientificK1632veretAid H Minus First-Strand cDNA virthesis KitThermo Fisher ScientificK1632cRNA sequencing dataGene Expression Omnibus (GEO)GSE116426cRNA sequencing dataGene Expression Omnibus (GEO)GSE116426cxperimental Models: Organisms/StrainsJackson Laboratories000664condectoridesee Table S6This paperN/Acondectoridesee Table S6Nonlinear Dynamics, Waters, Newcastle upon Tyne, U.K.N/A	oat anti-rabbit Ig-HRP	Dianova (Hamburg, Germany)	#111-035-003; RRID:AB2313567	
Chemicals, Peptides, and Recombinant Proteins CD11b (Microglia) MicroBeads, human and mouse Milteny Biotec 130-093-634 CD31 MicroBeads, mouse Milteny Biotec 130-097-418 CD31 MicroBeads UltraPure Milteny Biotec 130-105-637 Critical Commercial Assays EnvertAid H Minus First-Strand cDNA Thermo Fisher Scientific K1632 Synthesis Kit Thermo Fisher Scientific 12183016 EnvertAid H Minus First-Strand cDNA Ourse CRNA sequencing data Gene Expression Omnibus (GEO) GSE116426 Experimental Models: Organisms/Strains Janvier Labs SC-BALBJ-M S57BL/6J Janvier Labs SC-BALBJ-M Digonucleotides ee Table S6 This paper N/A Software and Algorithms Nonlinear Dynamics, Waters, Newcastle upon Tyne, U.K. N/A	abbit anti-goat Ig-HRP	Dianova (Hamburg, Germany)	#305-035-003; RRID:AB2339400	
D11b (Microglia) MicroBeads, human nd mouseMilteny Biotec130-093-634D31 MicroBeads, mouseMilteny Biotec130-097-418D31 MicroBeads UltraPureMilteny Biotec130-105-637Anti-Biotin MicroBeads UltraPureMilteny Biotec130-105-637Aritical Commercial AssaysEvertAid H Minus First-Strand cDNA synthesis KitThermo Fisher ScientificK1632PureLink® RNA Micro Scale KitThermo Fisher Scientific12183016PureLink® RNA Micro Scale KitThermo Fisher Scientific12183016PureLink® RNA Micro Scale KitGene Expression Omnibus (GEO)GSE116426Scrent Models: Organisms/StrainsJanvier LabsSC-BALBJ-MS57BL/6JJackson Laboratories000664NiligonucleotidesThis paperN/Aee Table S6This paperN/Arogenesis QI software for proteomics (ersion 3.0)Nonlinear Dynamics, Waters, Newcastle upon Tyne, U.K.N/A	oat anti-rabbit-IG-Cy3		#A10520; RRID:AB2534029	
nd mouse Milteny Biotec 130-097-418 2D31 MicroBeads, mouse Milteny Biotec 130-105-637 Stritical Commercial Assays RevertAid H Minus First-Strand cDNA Thermo Fisher Scientific K1632 Synthesis Kit PureLink® RNA Micro Scale Kit Thermo Fisher Scientific 12183016 Deposited Data CRNA sequencing data Gene Expression Omnibus (GEO) GSE116426 Streprimental Models: Organisms/Strains BALB/cJRj mice Janvier Labs SC-BALBJ-M 257BL/6J Jackson Laboratories 000664 Digonucleotides ee Table S6 This paper N/A Software and Algorithms Progenesis QI software for proteomics Nonlinear Dynamics, Waters, Newcastle upon Tyne, U.K.	Chemicals, Peptides, and Recombinant P	roteins		
Initi-Biotin MicroBeads UltraPure Milteny Biotec 130-105-637 Milteny Biotec 130-105-6		Milteny Biotec	130-093-634	
Dritical Commercial AssaysRevertAid H Minus First-Strand cDNAThermo Fisher ScientificK1632Synthesis KitThermo Fisher Scientific12183016PureLink® RNA Micro Scale KitThermo Fisher Scientific12183016Deposited DataGene Expression Omnibus (GEO)GSE116426cRNA sequencing dataGene Expression Omnibus (GEO)GSE116426Experimental Models: Organisms/StrainsJanvier LabsSC-BALBJ-MSALB/cJRj miceJanvier LabsSC-BALBJ-M257BL/6JJackson Laboratories000664DigonucleotidesThis paperN/ASoftware and AlgorithmsNonlinear Dynamics, Waters, Newcastle upon Tyne, U.K.N/A	CD31 MicroBeads, mouse	Milteny Biotec	130-097-418	
RevertAid H Minus First-Strand cDNA bynthesis KitThermo Fisher ScientificK1632PureLink® RNA Micro Scale KitThermo Fisher Scientific12183016PureLink® RNA Micro Scale KitThermo Fisher Scientific12183016Deposited DataCRNA sequencing dataGene Expression Omnibus (GEO)GSE116426CRNA sequencing dataGene Expression Omnibus (GEO)GSE116426Scher KurderJanvier LabsSC-BALBJ-MSALB/cJRj miceJackson Laboratories000664S7BL/6JJackson Laboratories000664DilgonucleotidesThis paperN/Aee Table S6This paperN/Arogenesis QI software for proteomics Version 3.0)Nonlinear Dynamics, Waters, Newcastle upon Tyne, U.K.N/A	nti-Biotin MicroBeads UltraPure	Milteny Biotec	130-105-637	
And Micro Scale Kit Thermo Fisher Scientific 12183016 Deposited Data CRNA sequencing data Gene Expression Omnibus (GEO) GSE116426 xperimental Models: Organisms/Strains ALB/cJRj mice Janvier Labs SC-BALBJ-M 257BL/6J Jackson Laboratories 000664 Digonucleotides ee Table S6 This paper N/A ee Table S6 Nonlinear Dynamics, Waters, Progenesis QI software for proteomics Nonlinear Dynamics, Waters, /ersion 3.0) Nonlinear Dynamics, Waters, /ersion 3.0) Nonlinear Dynamics, Waters, /ersion 3.0) Nonlinear Dynamics, Waters, /ersion 3.0) Nonlinear Dynamics, Waters, N/A	ritical Commercial Assays	· · · · · · · · · · · · · · · · · · ·		
Deposited Data Gene Expression Omnibus (GEO) GSE116426 Experimental Models: Organisms/Strains SALB/cJRj mice Janvier Labs SC-BALBJ-M SALB/cJRj mice Janvier Labs SC-BALBJ-M C57BL/6J Jackson Laboratories 000664 Digonucleotides Ee Table S6 This paper N/A Software and Algorithms Version 3.0) Nonlinear Dynamics, Waters, Newcastle upon Tyne, U.K. N/A		Thermo Fisher Scientific	K1632	
Gene Expression Omnibus (GEO) GSE116426 Experimental Models: Organisms/Strains SaLB/cJRj mice Janvier Labs SC-BALBJ-M SALB/cJRj mice Janvier Labs SC-BALBJ-M C57BL/6J Jackson Laboratories 000664 Digonucleotides This paper N/A Software and Algorithms Nonlinear Dynamics, Waters, Newcastle upon Tyne, U.K. N/A	PureLink® RNA Micro Scale Kit	Thermo Fisher Scientific	12183016	
Experimental Models: Organisms/Strains BALB/cJRj mice Janvier Labs SC-BALBJ-M C57BL/6J Jackson Laboratories 000664 Dilgonucleotides This paper N/A ee Table S6 This paper N/A Progenesis QI software for proteomics /ersion 3.0) Nonlinear Dynamics, Waters, Newcastle upon Tyne, U.K. N/A	Deposited Data			
Experimental Models: Organisms/Strains BALB/cJRj mice Janvier Labs SC-BALBJ-M C57BL/6J Jackson Laboratories 000664 Dilgonucleotides This paper N/A ee Table S6 This paper N/A Progenesis QI software for proteomics /ersion 3.0) Nonlinear Dynamics, Waters, Newcastle upon Tyne, U.K. N/A	cRNA sequencing data	Gene Expression Omnibus (GEO)	GSE116426	
Digonucleotides O00664 Digonucleotides This paper Software and Algorithms N/A Progenesis QI software for proteomics Version 3.0) Nonlinear Dynamics, Waters, Newcastle upon Tyne, U.K. N/A				
Diigonucleotides ee Table S6 This paper N/A Software and Algorithms Vorgenesis QI software for proteomics Nonlinear Dynamics, Waters, NA Progenesis QI software for proteomics Nonlinear Dynamics, Waters, Newcastle upon Tyne, U.K. N/A	BALB/cJRj mice	Janvier Labs	SC-BALBJ-M	
This paper N/A Software and Algorithms Nonlinear Dynamics, Waters, Progenesis QI software for proteomics Nonlinear Dynamics, Waters, Version 3.0) Newcastle upon Tyne, U.K.	C57BL/6J	Jackson Laboratories	000664	
Software and Algorithms Nonlinear Dynamics, Waters, N/A Progenesis QI software for proteomics Nonlinear Dynamics, Waters, N/A Version 3.0) Newcastle upon Tyne, U.K.	Digonucleotides			
rogenesis QI software for proteomics Nonlinear Dynamics, Waters, N/A /ersion 3.0) Newcastle upon Tyne, U.K.	ee Table S6	This paper	N/A	
Version 3.0) Newcastle upon Tyne, U.K.	Software and Algorithms			
•		Newcastle upon	N/A	
	R package Seurat	Stuart et al., 2019	N/A	

(Continued on next page)

Continued			
REAGENT or RESOURCE	SOURCE	IDENTIFIER	
FIJI (ImageJ)	National Institutes of Health, Bethesda, MD, USA	N/A	
<i>R</i> v 3.5.1	https://www.R-project.org	N/A	

LEAD CONTACT AND MATERIALS AVAILABILITY

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Diana Pauly (diana.pauly@ukr.de). This study did not generate new unique reagents.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Single cell RNA-Seq and RNA-FISH was performed on wild-type (C57BL/6J) male mice (10 weeks old) purchased from Jackson Laboratory (Bar Harbor, ME, USA). All experimental procedures were approved by the University of Pennsylvania Animal Care and Use Committee. Mice were sacrificed with cervical dislocation under anesthesia. Experiments for immunomagnetic separation were done in accordance with the European Community Council Directive 2010/63/EU and the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and were approved by the local Bavarian authorities (55.2 DMS-2532-2-182, Germany). All mice were housed in a 12 hour light/ dark cycle with ~400 lux. Experiments on complement expression in aging mice were conducted with 8, 16 and 24 week old male and female on BALB/c mice. Retinal ischemia was induced in one eye of 8 week old male and female C57BL/6J mice. The untreated contralateral eye served as internal control and, accordingly, an additional control group was not needed thereby sticking to the rules of the three R's by keeping reducing the number of animals used in respective experiments.

METHOD DETAILS

Retinal ischemia/ reperfusion injury

The protocols for induction of transient retinal ischemia were approved by the local Bavarian authorities (55.2 DMS-2532-2-182, Germany). Ischemia was induced in one eye of 8 week old male and female C57BL/6J mice using the high intraocular pressure (HIOP) method (Pannicke et al., 2014; Wagner et al., 2016). The other eye remained untreated and served as an internal control. Anesthesia was induced with ketamine (100 mg/kg body weight, intraperitoneal (ip); Ratiopharm, Ulm, Germany), xylazine (5 mg/kg, ip; Bayer Vital, Leverkusen, Germany), and atropine sulfate (100 mg/kg, ip; Braun, Melsungen, Germany). The anterior chamber of the test eye was cannulated from the pars plana with a 30-gauge infusion needle, connected to a saline bottle. The intraocular pressure was increased to 160 mmHg for 90 minutes by elevating the bottle. After removing the needle, the animals survived for 24 hours and subsequently, they were sacrificed with carbon dioxide for tissue analyses.

Single Cell RNA Analysis of mouse retina

Mouse eyeballs were quickly removed and placed in cold phosphate buffered saline (PBS). The mouse retina was carefully removed under dissecting scope and tissue was dissociated immediately using the papain dissociation system (Worthington, Lakewood, NJ, USA) following the manufacturer's instructions. Briefly, the mouse retina was incubated at 37° C for 30 minutes in Eagle's Balanced Salt Solution (EBSS) with DNase followed by tissue trituration with a 10 mL pipette. Cell pellet was collected after centrifugation at $300 \times g$ for 5 minutes and then resuspended in DNase albumin-inhibitor solution. The cell suspension was carefully layered on top of the albumin-inhibitor solution, then centrifuged at $70 \times g$ for 6 minutes. The cell pellet was washed and resuspended in 1:1 DMEM/ F12 + 10% FBS. All centrifugation steps were performed at room temperature. The final cell suspension was filtered with 40 μ m cell strainer (Falcon, Corning, NY, USA) to remove large debris. To assess cell viability, cells were stained with 0.4% trypan blue (Mediatech, Inc., Manassas, VA, USA) and counted using a hemocytometer. Viable cells (greater than 80%) were submitted to the Center for Applied Genomics at the Children's Hospital of Philadelphia (CHOP) for cell separation and lysis on the 10X Chromium Genomics instrument and sequencing on the Illumina Hi-Seq instrument.

All analyses were carried out in the statistical software R v 3.5.1. The R package Seurat was used for data analysis, dataset merging and cell clustering analysis. For clustering, we used 2000 or more genes that had detectable expression with high variability in the ~92,000 mouse retinal cells. Six genetically identical C57BL/6J mice were sequenced, our data were consistent across different batches (Figure S1). We filtered out low-quality cells in which < 90% of the reads did not map to the genome using the Cell Ranger pipeline from 10x genomics, and ultimately obtained 92,343 cells used in our subsequent analyses. Given the consistent number of genes (*nGene*), UMIs (*nUMI*), and the percentage of mitochondrial genes (*percent.mito*) detected in each batch, we merged the sequencing runs and used 30 principal components as an input to t-distributed stochastic neighbor embedding (t-SNE) method for dimension reduction and data visualization. We found 25 cell clusters within the retina using an unsupervised analysis that did not rely on known markers of retinal cells. Marker genes were identified for all clusters with the function *markers.all* in the R package Seurat; all marker genes with power less than 0.4 were discarded. Moreover, only cells with mitochondrial gene percentages < 50%, and those with unique gene counts between 200 and 3,500 were used, leaving us with 91,798 retinal cells. After filtering, we sought to consolidate the 25 clusters into a total of 11 (for N = 91,798 cells), each of which represents a major, functionally important cell class in the retina. For this, we used the known, established marker genes for common retinal cell types summarized in Table S1. Although previous studies of scRNA-seq on the mouse retina have identified more than 30 different cell types, this difference is largely explained by their subdivision of bipolar cells (BCs) into numerous sub-categories. We decided to classify cell types based on general categories because we wanted to study complement expression in retinal cells more broadly. Using this approach, the cell type proportions in the retina proper are comparable between our study and past studies. Based on mean complement gene expression, we categorized positive expression for a gene within a cell type only if either $\geq 5\%$ of cells or at least 50 cells within that class had non-zero expression for that gene.

RNA-FISH

Mouse protocol was approved by the University of Pennsylvania IACUC committee. A 10 week old C57BL/6J male was euthanized with 5 mg pentobarbital sodium. The eye was dissected free from the orbit, washed in PBS, embedded in OCT (Tissue Tek, Sakura Finetek USA, Torrance, CA, USA) and immediately snap-frozen in liquid nitrogen. The frozen tissue was sliced at 10 μ m on a cryostat and stored at -80° C on glass slides.

Tissue fixation and RNA in situ hybridization (RNA-FISH) was carried out using Stellaris® RNA FISH (LGC Biosearch Technologies, Petaluma, CA, USA) following the manufacturer's instructions. Briefly, the tissue section was fixed in 3.7% formaldehyde in 1X PBS for 10 minutes at room temperature. After washing twice with 1X PBS, the tissue section was permeabilized in 70% ethanol for at least 1 hour at room temperature. Oligo probes were designed against mRNA coding sequence for each gene using the Stellaris Custom probe sets and labeled with Quasar® 570 dye or Quasar® 670 dye. For a positive control, mouse GAPDH probe (Stellaris ShipReady probe sets) was purchased. To secure tissues on the slide during hybridization, the HybriWell® sealing system (Grace Bio-Labs, Bend, OR, USA) was used. Each tissue section was incubated in hybridization buffer containing probe (final concertation was between 62.5 nM to 250 nM) overnight at 37°C and then washed in washing buffer A for 30 minutes at 37°C. Cell nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI, 0.1 µg/ml) followed by washing in Buffer B. All buffers were purchased from LGC Bioresearch Technologies. Finally, mounting medium (ProLong Gold antifade reagent, Invitrogen, Life Technologies, Eugene, OR, USA) was added and a coverglass was mounted on the slide. Confocal microscopy to image the RNA-FISH samples was performed at the Bioimaging Core Facility of the Biomedical Center of the LMU Munich. RNA FISH images were obtained with an inverted Leica SP8X WLL microscope with a 63x/1.3 Glyc objective. We sequentially recorded Quasar 670 (excitation 647 nm; emission 670 nm -760 nm) and Quasar 570 (excitation 556 nm; emission 566 nm - 630 nm) with hybrid photo detectors (HyDs) and DAPI (excitation 405 nm; emission 415 nm - 450 nm) with a conventional photomultiplier tube. The same illumination and acquisition settings were used for all sections. Brightness and contrast of the images were adjusted with the open source software FIJI (ImageJ; National Institutes of Health, Bethesda, MD, USA).

MACS enrichment of retinal cell types

Retinal cell types were enriched as described previously using magnetic-activated cell sorting (MACS) (Grosche et al., 2016). Briefly, retinae were treated with papain (0.2 mg/ml; Roche Molecular Biochemicals) for 30 minutes at 37°C in the dark in Ca²⁺ - and Mg²⁺-free extracellular solution (140 mM NaCl, 3 mM KCl, 10 mM HEPES, 11 mM glucose, pH 7.4). After several washes and 4 minutes of incubation with DNase I (200 U/ml), retinae were triturated in extracellular solution (now with 1 mM MgCl₂ and 2 mM CaCl₂). To purify microglial and vascular cells, the retinal cell suspension was subsequently incubated with CD11b- and CD31 microbeads according to the manufacturer's protocol (Miltenyi Biotec, Bergisch Gladbach, Germany). The respective binding cells were depleted from the retinal suspension using LS-columns, prior to Müller cell enrichment. To purify Müller glia, the cell suspension was incubated in extracellular solution, spun down, resuspended in the presence of anti-biotin MicroBeads (1:5; Miltenyi Biotec,) and incubated for 10 minutes at 4°C. After washing, CD29+ Müller cells were separated using large cell (LS) columns according to the manufacturer's instructions (Miltenyi Biotec). Cells in the flow through of the last sorting step- depleted of microglia, vascular cells and Müller glia-were considered as the neuronal population. RPE was collected by scratching the eye cup after the retina had been removed and thus, scratch samples also contained cells from the underlying choroid. Samples were digested, and in subsequent steps, macro-phages were depleted using anti-CD11b-microbeads and vascular cells using CD31-microbeads (Miltenyi Biotec).

qRT-PCR

Total RNA was isolated from the enriched cell populations using the PureLink[®] RNA Micro Scale Kit (Thermo Fisher Scientific, Schwerte, Germany). A DNase digestion step was included to remove genomic DNA (Roche). We performed RNA integrity validation and quantification using the Agilent RNA 6000 Pico chip analysis according to the manufactures instructions (Agilent Technologies, Waldbronn, Germany). First-strand cDNAs from the total RNA purified from each cell population were synthesized using the RevertAid H Minus First-Strand cDNA Synthesis Kit (Fermentas by Thermo Fisher Scientific, Schwerte, Germany). We designed primers using the Universal ProbeLibrary Assay Design Center (Roche, Table S6) and measured transcript levels of candidate genes

by qRT-PCR using the TaqMan hPSC Scorecard Panel (384 well, ViiA7, Life Technologies, Darmstadt, Germany) according to the company's guidelines.

LC-MS/MS mass spectrometry analysis

LC-MS/MS analysis was performed as described previously (Frik et al., 2018; Lepper et al., 2018) on a Q-Exactive HF mass spectrometer (Thermo Fisher Scientific Inc., Waltham, MA, U.S.A.) coupled to an Ultimate 3000 RSLC nano-HPLC (Dionex, Sunnyvale, CA). Briefly, 0.5 µg sample was automatically loaded onto a nano trap column (300 µm inner diameter × 5 mm, packed with Acclaim PepMap100 C18. 5 μm, 100 Å; LC Packings, Sunnyvale, CA) before separation by reversed phase chromatography (HSS-T3 M-class column, 25 cm, Waters) in an 80 minutes non-linear gradient from 3 to 40% acetonitrile (ACN) in 0.1% formic acid (FA) at a flow rate of 250 nl/min. Eluted peptides were analyzed by the Q-Exactive HF mass spectrometer equipped with a nano-flex ionization source. Full scan MS spectra (from m/z 300 to 1500) and MS/MS fragment spectra were acquired in the Orbitrap with a resolution of 60,000 or 15000 respectively, with maximum injection times of 50 ms each. Up to ten most intense ions were selected for HCD fragmentation depending on signal intensity (TOP10 method). Target peptides already selected for MS/MS were dynamically excluded for 30 s. Spectra were analyzed using the Progenesis QI software for proteomics (Version 3.0, Nonlinear Dynamics, Waters, Newcastle upon Tyne, UK) for label-free quantification, as previously described (Grosche et al., 2016). All features were exported as a Mascot generic file (mgf) and used for peptide identification with Mascot (version 2.4) in the UniProtKB/Swiss-Prot taxonomy mouse database (Release 2017.02, 16871 sequences). Search parameters used were: 10 ppm peptide mass tolerance, 20 mmu fragment mass tolerance, one missed cleavage allowed, carbamidomethylation set as fixed modification, and methionine oxidation, asparagine or glutamine deamidation were allowed as variable modifications. A Mascot-integrated decoy database search calculated an average false discovery rate (FDR) of < 1%.

Western blot

Cell pellets of enriched cell populations from pooled pair of mouse eyes were dissolved in reducing Laemmli sample buffer, denatured and sonicated. Neuronal protein extraction reagent (Thermo Fisher Scientific, Braunschweig, Germany) was added to the neuron populations. Samples were separated on a 12% SDS-PAGE. The immunoblot was performed as previously described (Schäfer et al., 2017). Detection was performed with primary and secondary antibodies diluted in blocking solution (Table S7). Blots were developed with WesternSure PREMIUM Chemiluminescent Substrate (LI-COR, Bad Homburg, Germany). To validate specificity of the antibodies, all of them were tested on mouse serum as positive control (Figure S3).

Immunofluorescent labeling of retina and RPE

To quantify cell nuclei and perform stainings for C1s, C3 and glutamine synthetase (GLUL) in retinal sections of 4% paraformaldehyde (PFA)-fixated and paraffin-embedded murine eyes, the sections were deparaffinised and incubated with Hoechst33342/DAPI (1:1000; #H1399, Thermo Fisher Scientific, Braunschweig, Germany) or detection antibodies as previously described (Schäfer et al., 2017) (Table S7). Images were acquired using confocal microscopy (VisiScope, Visitron Systems, Puchheim, Germany).

Retinal microglia quantification was performed in the retinal flat mounts. Anterior segments of mouse eyes were removed, and the retina carefully separated. Flat mounts were fixated in 4% PFA (retina 1 h room temperature), permeabilized (1% Triton X-100) and blocked (1% BSA, 5% goat serum, 0.1 M NaPO₄, pH 7). Retinal flat mounts were stained with anti-Iba1 antibody (3% Triton X-100, 1% DMSO, 5% normal goat serum, overnight at 4°C) and secondary antibody (1% BSA in PBS, overnight at 4°C) (Table S7). Retinal flat mounts were embedded with photoreceptors facing down, and the GCL facing up. Images were taken with a confocal microscope (VisiScope, Visitron Systems).

QUANTIFICATION AND STATISTICAL ANALYSIS

Statistical analyses were performed using Prism (Graphpad Software, San Diego, CA, USA). In most of the experiments in the present study results from 4 biological replicates were collected to keep to the rules of the three Rs for the sake of animal welfare. Since this low number of input values does not allow an appropriate estimation about a normal Gaussian distribution, significance levels were determined by the non-parametric Mann-Whitney U test unless stated otherwise. All data are expressed as mean ± standard error (SEM) unless stated otherwise. Detailed information about specific n-values, implemented statistical tests and coding of significance levels are provided in the respective figure legends.

DATA AND CODE AVAILABILITY

The accesssion number for the single cell RNA-Seq data reported in this paper is GSE116426 (Gene Expression Omnibus (GEO)). Other data supporting the findings of this study are available from the corresponding author upon request.